



European Curriculum Vitae

Personal information

First name / Surname	Claudio Cerchione, MD, PhD
Date of birth	19/02/1984
Gender	M
Nationality	Italian
Language	Italian (native tongue), English, German, Spanish
Work Address	Dirigente Medico ricercatore – Phase 1 Trials Board - Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola (FC), Italy
Personal Address	Via Ferruccio Parri 2, 47121, Forli (FC), Italy
Personal Mobile phone	+39 3475533565
Work phone	+39 0543 739100
Work E-mail	claudio.cerchione@irst.emr.it
Personal E-mail	claudiocerc@hotmail.com
University	Adjunct Professor – Department of Pharmacology and Biotechnology – University of Bologna
Membership	EMA Scientific Advisory Group Onco-Hematology – Board Member President of Society of Hematologic Oncology (SOHO) Italy Ambassador of SOHO (Society of Hematologic Oncology) ASH (American Society of Hematology) EHA (European Society of Hematology) EMN (European Myeloma Network) SIE (Società Italiana di Ematologia) SIES (Società Italiana di Ematologia Sperimentale) AIL (Associazione Italiana contro le Leucemie, Linfomi, Mielomi) AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica)

	ACLTi (Associazione contro le Leucemie e i Tumori dell'Infanzia) Rotary Club
Degree	Degree in Medicine, University Federico II, Napoli, Italy, 110 cum laude, July 2008 (Final thesis in Hematology–New TKI in CML)
Professional Medical Qualification	270/270, February 2009, School of Medicine – University Federico II, Naples, Italy
Residency	Hematology, 50 cum laude, July 2014, University Federico II, Naples, Italy Italy (Final Thesis in Myelodysplastic Syndromes)
PhD program	Newer biomedical and Surgical treatments, Department of Clinical Medicine and Surgery - University Federico II, Naples, Italy (Tutor prof Fabrizio Pane - Director prof Giovanni Di Minno) Ottimo cum laude, May 2017, University Federico II, Naples, Italy Italy (Final Thesis in Multiple Myeloma)
European Hematology Exam	European Hematology Exam (EHA - European Society of Hematology), 12 June 2018
Transplants	Accreditation JACIE since 2018
AIL	Home care doctor in Adult Hematology (since November 2014) Home care doctor in Pediatric Hematology (since May 2015)
Volunteer Membership	Scientific Responsible of ACLTi (Associazione contro le Leucemie e i Tumori dell'Infanzia)
Emergency Medical Service	ASL Napoli 1 (also Secondigliano Jail, Naples) (September 2011 – June 2014)
Experience as Specialist	Pediatric OncoHematology A.O.R.N. Santobono-Pausilipon Hospital July 2014 – August 2018
Ambassador	Ambassador of Society of Hematologic Oncology (SOHO) – MD Anderson Cancer Center for Italy, since 2019 (Responsible Prof. H. Kantarjian)
Membership - details	<ol style="list-style-type: none"> 1) AIL (Associazione Italiana contro Leucemie-Linfomi-Mielomi) since 2009 2) SIE (Società Italiana di Ematologia) since 2009 3) SIES (Società Italiana di Ematologia Sperimentale) since 2016 4) EHA (European Hematology Association) since 2009 5) AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) since 2015 6) SOHO (Society of Hematologic Oncology) since 2017, Ambassador since 2019 7) ASH (American Society of Hematology) since 2017 8) ACLTi (Associazione contro le Leucemie e i Tumori dell'Infanzia) – Scientific Responsible – since 2017

	9) Rotary Club – since 2017 10) EMN (European Myeloma Network) – Italy – Board member of relapsed/refractory panel 11) EMN (European Myeloma Network) – Europe – Board member since 2019 12) SOHO (Society of Hematologic Oncology) Italy – President and Founder since 2019
Work experiences	
	Clinical and Research Collaboration with Leukemia Department of MD Anderson Cancer Center and Ambassador for Italy of Society of Hematologic Oncology (SOHO) (Director Prof H. Kantarjian - Houston, Texas, USA)
2019 – Today	Adjunct Professor – Department of Pharmacy and Biotechnology
September 2018	Winner of Clinical Research Training in Hematology (CRTH) – European Hematology Association (EHA) 2018/2019
September 2018 – Today	“Dirigente Medico” in Hematology – IRST IRCCS Meldola (FC) – Italy (included in Phase 1 board)
September 2018 – Today	Scientific Projects in Pediatric OncoHematology (<i>Supervision Dott. M. Ripaldi</i>), OncoHematology Department, A.O.R.N. Santobono-Pausilipon, Naples, Italy.
May 2018 – Today	Scientific Projects in Hematological Malignancies (<i>Supervision Prof. F. Pane</i>), Hematology Division, Department of Clinical Medicine and Surgery, University “Federico II”, Naples, Italy.
Sep 2017 - Today	Scientific Projects in Hematological Malignancies (<i>Supervision Prof. F. Ferrara</i>), Hematology Division, A.O.R.N. Cardarelli, Naples, Italy.
September 2014 – Aug 2018	In charge for Clinical management of Multiple Myeloma/MGUS (<i>Supervision Prof. F. Pane</i>), Hematology Division, Department of Clinical Medicine and Surgery, University “Federico II”, Naples, Italy.
July 2014 – Aug 2018	Pediatric OncoHematology, Santobono-Pausilipon Hospital, Naples, Italy
July 2009 – July 2014	Residency in Hematology, Hematology Division, Department of Clinical Medicine and Surgery, University “Federico II”, Naples, Italy. - Clinical management of Chronic Myeloid Leukemia, Anemia and Myelodysplastic syndromes, Lymphoproliferative disorders (particularly non-Hodgkin and Hodgkin Disease and CLL), Pediatric Oncohematology, Multiple Myeloma and Ph- Myeloproliferative neoplasm, Autologous and Allogenic Bone Marrow Transplantation.

Sep 2006 – June 2009	Visitor Student, Hematology Division, University of Naples “Federico II”, Italy
Sep 2008 – Oct 2008	Visitor Medical Student (Clinical Clerkship) – Research and clinical activities in Hematology Department, Hospitais da Universidade de Coimbra (Director prof Adriana Teixeira), Portugal
Sep 2005 – Sep 2006	Visitor Medical Student (Erasmus project) – Research and clinical activities in Hematology Department, Friedrich-Wilhelms Universitat Bonn (Director prof Schmidt Wolf), Germany
Sep 2002 – July 2008	Medical Graduation, School of Medicine “Federico II”, Italy
September 1997 – June 2002	High school Graduation, Scientific Lyceum “N. Copernico”, Naples, Italy (Final mark 100/100)
Clinical investigation	
Feb 2015 – Today	Co-responsible [during PhD program] in clinical trial for Acute Leukemias performed in Hematology Division, Federico II, Naples, Italy (Front-line central vascular access devices in acute leukemias – peripherally inserted catheter (PICC) versus traditional venous catheter (CVC) : a phase IV randomized trial (NCT02405728))
Sep 2011 – Today	Partecipation in RECAMDS (Regional Myelodysplasic Syndromes Register)
Mar 2012 – Today	<p>Sub-investigator of following clinical trial (GCP Training: 15/06/2011, University Federico II, Naples, Italy):</p> <ul style="list-style-type: none"> • “MORE” –Revlimid/Lenalidomide in del 5q syndrome (Celgene) • Denosumab in Multiple Myeloma (AMGEN) • Pegilated GCSF in LNH (TEVA) • GOYA (LNH, ROCHE) • TOWER-AMG103 (Blinatumomab in LLA) <p>Responsible of Compassionate Use Program for new drugs in Multiple Myeloma:</p> <ul style="list-style-type: none"> • Daratumumab • Carfilzomib • Ixazomib
Sep 2018 – Today	<p>Principal Investigator of following clinical trials (IRST IRCCS Meldola (FC)):</p> <ul style="list-style-type: none"> • A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma (Phase 1 – NCT03486067) • DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma (Phase 3 - NCT04246047)

- A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia (Phase 3 - NCT03616470)
- A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma (Phase 3 - NCT04270409)
- A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (Phase 3 - NCT03173248)
- Phase 1-2 trial evaluating anti-TGFbeta agent (SAR439459) or pomalidomide in combination with isatuximab and dexamethasone in relapsed or refractory multiple myeloma (Phase 1 - ACT16482)
- A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (Phase 1 - NCT04570631)
- SKY92 plus Integrated Multidisciplinary approach to detect New Prognostic Index in Multiple Myeloma (SIMPI)

Observational Trials

- Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting B-cell Lymphoma 2 (BCL-2) (NCT04070807)
- A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment (NCT04035226)
- ABVD vs BEACOPP in HL
- StreamMing,
- Impact of novel agents in clinical management in real world of hematological malignancies (IRST),
- Impact of novel agents in clinical management in real world of Multiple Myeloma (IRST),
- Prospective Comparison between whole body MRI plus FDG-PET/CT and FDG-PET/CT in Multiple Myeloma (IRST)
- Protocollo SEIFEM Prospettico sulle Complicanze Infettive in pazienti trattati in prima linea con Demetilanti da soli o in associazione con Venetoclax o altri farmaci.
- Studio osservazione SEIFEM Vyxeos
- EMN COVID
- EMN - Real-life use of Carfilzomib, lenalidomide and dexamethasone (KRd)
- A retrospective and prospective multicentre observational study for the evaluation of incidence of familial AML/MDSs in patients with myeloid neoplasms (AML/MDS)"

Sub-investigator of many clinical trial (IRST IRCCS Meldola (FC)), some of which are:

- PAC203
- EMN17 - Perseus
- UNITO-MM01 - Forte (Multiple Myeloma)
- Real MM
- FIL-ROUGE
- Triangle
- PCYC-1143CA
- FOLL-12
- Citadel 204
- V-RBAC
- ACE 006
- ACE-CL-007
- RV-MM PI-0752

Fields of interest and research

- Clinical management and research on Multiple Myeloma and MGUS, with particular interest in imaging diagnostic techniques, alternative chemotherapy regimens in relapsed/refractory patients and transplantation procedures,
- Clinical management and research on Acute Lymphoblastic and Acute Myeloid Leukemia with particular interest in alternative chemotherapy regimens in relapsed/refractory patients,
- Clinical management and research on Chronic Myeloid Leukemia and Ph- Myeloproliferative neoplasms, with research interest on mechanisms of second generation TKIs.
- Clinical management and research of Myelodysplastic Syndromes and Acute Leukemias, with particular interest on role of demethylating agents.
- Clinical management and research of Hodgkin and non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
- Clinical management and research of Pediatric Acute Leukemias
- Clinical management and research of Infections in Hematologic patients, with particular interest in diagnostic tools and imaging techniques, especially for invasive fungal infections
- Clinical management and research of Myelodysplastic Syndromes and Acute Leukemias, with particular interest on role of demethylating agents.
- Clinical management and research of Autologous and Allogenic Bone Marrow Transplantation (JACIE Certificate)

Education and training

15 May 2017	Ph.D., Hematology Division, University of Naples, Italy, with full marks, cum laude.
30 June 2009	Residency in Hematology, University of Naples, Italy, with full marks, cum laude.
22 July 2002	M.D., University of Naples, Italy, with full marks, cum laude.

Personal skills and competences

Native Speaking

Italian

Other language

English (Certificate C1.2 British Council, Naples, Italy)

Understanding	Speaking	Writing
Excellent	Excellent	Excellent

German (Certificate B2, Rheinische Friedrich-Wilhelms Universitat, Bonn, Germany)

Understanding	Speaking	Writing
Very Good	Very Good	Very Good

Personal skills and competences

Computer skills and competences

Excellent knowledge of Office packages (Word, Excel, Power-point), Internet Explorer, Google Chrome, Mozilla Firefox and E-mail client (Outlook express), Operating systems (Microsoft Windows and Mac OS)

User of statistical program (STAT v7, SPSS).

Driving licence

European Driving license, type B

BLSD (Basic Life Support early Defibrillation)

(17/07/2010 - AOU Federico II – Napoli – Italy; 20/09/2018 – IRST IRCCS – Forlimpopoli)

P.T.C. (Pre-Hospital Trauma Care) (18/09/2010)

AOU Federico II – Napoli - Italy

BLSD (Basic Life Support Early Defibrillation) (20/09/2018)

IRST – IRCCS – Meldola (FC) – Italy

ALS (Advanced Life Support) (22-23/03/2019)

IRST – IRCCS – Meldola (FC) – Italy

Teaching

Research Teaching Assistant (“Cultore della materia”) in Hematology - University of Ferrara, Italy

- 1) Medicine and Surgery

Research Teaching Assistant (“Cultore della materia”) in Hematology - University Federico II, Naples, Italy

- 1) Medicine and Surgery
- 2) Biotechnology
- 3) Laboratory technicians
- 4) Radiology technicians

Research Teaching Assistant

- 1) Training a field force – Teacher for AMGEN Staff (Santa Margherita di Pula (Cagliari), Italy)
- 2) Training Ixazomib in Multiple Myeloma for Takeda Staff (Rome and Milan)

Advisory Board/Consultant

- 1) Multiple Myeloma
- 2) Acute Myeloid Leukemia
- 3) Acute Lymphoblastic Leukemia
- 4) Waldenstrom Disease
- 5) Chronic Lymphocytic Leukemia

Member of Scientific Committee

- 1) EUBEA
- 2) Proeventi

International and National Awards

- 1) **Winner of Clinical Research Training Program in Hematology (European Society of Hematology - EHA) 2018/2019**
- 2) Travel Grant winner at the 8th Stem Cell Course- Collegio Ghislieri, Pavia
- 3) Travel Grant winner at the 9th Stem Cell Course- Collegio Ghislieri, Pavia
- 4) Travel Grant winner at the 10th Stem Cell Course- Collegio Ghislieri, Pavia
- 5) Travel Grant winner at the 11th Stem Cell Course- Collegio Ghislieri, Pavia
- 6) Travel Grant winner at the 12th Stem Cell Course- Collegio Ghislieri, Pavia
- 7) Travel Grant winner at the 13th Stem Cell Course- Collegio Ghislieri, Pavia
- 8) iAcademy Award 2013 – Napoli
- 9) Travel Grant winner at Brain training in Hematology: Casi clinici stimolanti e allocuzioni lungimiranti 2013 (Italian Society of Hematology, Pesaro, Italy)
- 10) iAcademy Award 2014 – Napoli
- 11) Travel Grant winner at Corso Innovazioni in Ematologia 2014 (Italian Society of Hematology, Pesaro, Italy)
- 12) Winner of Progressi in Ematologia – I giovani come protagonisti - SIE Giovani (Stazione Marittima, Napoli)
- 13) Travel Grant winner at the 15th Stem Cell Course- Collegio Ghislieri, Pavia
- 14) Travel Grant winner at Ematologia nel 2015: come sta cambiando la musica (Italian Society of Hematology, Pesaro, Italy)
- 15) Travel Grant winner at SIES (Società Italiana Ematologia Sperimentale) congress 2016, Rimini
- 16) Travel Grant winner at Nuovo Cinema in Ematologia 2016 (Italian Society of Hematology, Pesaro, Italy)
- 17) Travel Grant winner at Novità in Ematologia, Modena, Italy

- 18) Travel Grant winner (with Oral Communication) at EHA 2017, Madrid
- 19) Travel Grant winner at SOHO 2017, Houston, Texas, USA
- 20) Travel Grant winner at Springer Rising Medical Stars – High Formation Program, Milan, Italy
- 21) Rotary Club Volunteer prize 2018
- 22) Travel Grant winner at SOHO 2018, Houston, Texas, USA
- 23) Travel Grant winner at SIES (Società Italiana Ematologia Sperimentale) congress 2018, Rimini
- 24) Travel Grant winner at EHA 2020

Editorial Board Membership

- 1) **Associate Editor in Frontiers in Oncology**
- 2) **Associate Editor in Supportive Care in Cancer**
- 3) **Associate Editor in Turkish Journal of Hematology**
- 4) **Associate Editor in Hematology Reports**
- 5) **Guest Editor in Minerva Medica**
- 6) **Guest Editor in Panminerva Medica**
- 7) **Guest Editor in International Journal of Molecular Sciences**
- 8) **Guest Editor in Cancer Drug Resistance**

Oral presentations national and international events:

- 1) **Successful pregnancies in Chronic Myeloid Leukaemia male patient on Imatinib therapy**
Annual meeting of "Centri di Ematologia Meridionale ed Insulare" (SIE SUD), 28-29 October 2010, Castellaneta Marina (Taranto, Italy)
- 2) **Renal failure associated to tyrosine kinase inhibitors**
Annual meeting of "Centri di Ematologia Meridionale ed Insulare" (SIE SUD), 28-29 October 2010, Castellaneta Marina (Taranto, Italy)
- 3) **Monitoraggio dei livelli plasmatici degli antimicotici azolici nei pazienti neutropenici e correlazioni con efficacia terapeutica ed effetti tossici**
Under40 Project in Hematology, 15-16 November 2012, Napoli, Italy
- 4) **Terapia combinata con voriconazolo e caspofungina: una nuova arma contro l'Aspergilloso invasive**
iAcademy Award 2013 – 22 November 2013, Napoli, Italy
- 5) **Ruolo della Bendamustina nel paziente con Mieloma Multiplo Recidivato e Refrattario**
Policlinico AOU Federico II – 3 April 2014, Napoli, Italy
- 6) **Analisi della risposta agli agenti eritrostimolanti in una coorte di pazienti affetti da syndrome mielodisplastica low-risk afferenti al Registro Campano per le MDS**
Italian Red Cell Club 2014 – 3-4 October 2014, San Marcellino e Festo – Napoli, Italy
- 7) **Efficacia del Voriconazolo nell'aspergilloso refrattario alla terapia con amfotericina B : la nostra esperienza**
iAcademy Award 2014 – 27 November 2014, Avellino, Italy
- 8) **Lo Sportello Giovani dell'Ordine dei Medici di Napoli incontra i Medici in Formazione 2014/2015**
(2 March 2015, Policlinico Federico II, Napoli)
- 9) **Mieloma Multiplo: Strategie a confronto: Switch: bilancio tra sostenibilità ed efficacia**
23 April 2015, Hotel Royal – Napoli
- 10) **Il mielodisplastico alto rischio: ruolo degli agenti ipometilanti**
La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – II Edizione – 4 June 2015, Hotel Montespina, Napoli
- 11) **Il mielodisplastico non trasfusione dipendente: ruolo dell'Epoietina**
La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – II Edizione – 4 June 2015, Hotel Montespina, Napoli
- 12) **Mieloma Multiplo – Winner of Progressi in Ematologia I giovani come Protagonisti - 4-5 marzo 2016, Napoli**
- 13) **Il Mieloma Multiplo: innovazioni nei trattamenti di prima linea e linee successive**
La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – III Edizione – 16 June 2016, Hotel Montespina, Napoli
- 14) **Il mielodisplastico non trasfusione dipendente: ruolo dell'Epoietina**

La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – III Edizione – 16 June 2016, Hotel Montespina, Napoli

- 15) **L'esperto risponde – Training a field force – Riunione di ciclo AMGEN**
15 September 2016 - Fortevillage – Santa Margherita di Pula (Cagliari)
- 16) **Mieloma Multiplo - Esperienze di pratica clinica: dalle opzioni terapeutiche alla strategia terapeutica**
Il Mieloma Multiplo - 5 May 2017, Hotel Royal, Napoli
- 17) **Il trattamento del Mieloma Multiplo recidivato-refrattario**
Il valore dell'immuno-oncologia nel Mieloma Multiplo, 6 June 2017, Tavola Rotonda BMS, Policlinico Federico II, Napoli
- 18) **Il trattamento medico dell'anemia nella pratica clinica con Epoietina**
La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – IV Edizione – 15 June 2017, Hotel Montespina, Napoli
- 19) **Il Mieloma Multiplo: innovazioni nei trattamenti di prima linea e linee successive**
La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – IV Edizione – 15 June 2017, Hotel Montespina, Napoli
- 20) **Front-line vascular access devices in acute leukemias – Peripherally inserted central catheter (PICCs) versus traditional central venous catheter (CVCs): a phase IV randomized trial (NCT02405728)**
Oral communication - European Hematology Association (EHA) 2017, 24 June 2017, Madrid, Spain
- 21) **L'immunoterapia: una tripletta differente - Il Mieloma Multiplo: dalla prima linea alla recidiva – 30 September 2017, Naples, Italy**
- 22) **Front-line vascular access devices in acute leukemias – Peripherally inserted central catheter (PICCs) versus traditional central venous catheter (CVCs): a phase IV randomized trial – an update (NCT02405728)**
Oral communication – Italian Society of Hematology 2017, 16 October 2017, Roma, Italy
- 23) **Leucemia Mieloide Cronica – l'ingresso in clinica dei generici: opportunità e preoccupazioni. La Medicina Narrativa nell'era della Precision Medicine – Le Medical Humanities in Ematologia, Oncologia e Terapia del dolore – 10 November 2017, Sala Convegni Croce Rossa Italiana, Naples, Italy**
- 24) **L'approccio terapeutico nel Mieloma Multiplo – Nuovi scenari in Ematologia, 1 December 2017, Palazzo Esedra, Naples, Italy**
- 25) **Lenalidomide in Mantle Cell Lymphoma Patients and MRD status in MRD: clinical impact in hematological malignancies – School of NGS - 7 September 2018 - IRST IRCCS Meldola (FC)**
- 26) **Training Ixazomib in Multiple Myeloma – Takeda Italia – Roma + Bologna, 12 September, 10 October 2018**
- 27) **Moderatore Sessione “Registry, big data and interpretation” in “Nuove frontiere del NGS nella diagnostica ematologica” - 25 October 2018 – IRST IRCCS Meldola (FC)**

- 28) **Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy**
Oral communication – Italian Society of Experimental Hematology 2018, 18 October 2018, Rimini, Italy
- 29) **Relatore “IMiDs e la modulazione del microambiente nel Mieloma Multiplo: le nuove indicazioni della Lenalidomide e nuove opportunità della Pomalidomide” in “L’ematologia, l’Oncologia e la medicina del dolore tra umanizzazione delle cure e precision medicine”** – 26 October 2018 - Sala Convegni Croce Rossa Italiana – Napoli
- 30) **Scientific Responsible of First Master in Pediatric OncoHematology** – A.O.R.N. Santobono-Pausilipon – Napoli – 2018/2019 – Talks 1) **Introduzione al Master e all’Ematologia Pediatrica**, 2) **Diagnostica delle patologie ematologiche**, 3) **Terapia di supporto nel bambino emopatico – Il ruolo dei fattori di crescita**
- 31) **Perceptorship Training Program** – Optimizing Outcomes for Patients with Acute Lymphoblastic Leukemia – International Faculty Member + Speaker – 16-17 January 2019 – **MD Anderson Cancer Center (Houston, Texas, USA)**
- 32) **Iron deficiency in neonatology and pediatrics: State of the art - International Multidisciplinary Course on Iron Deficiency (IMCID)** – 8-9 March 2019 – NH Collection Roma Vittorio Veneto –Rome, Italy
- 33) **DLI plus Immunotherapy in ALL - XI International Florence meeting on Hematology** – Focus on treatment in difficult scenarios – 4-5 April 2019 – Rettorato University of Florence – Florence, Italy
- 34) **Keynote speech – Report sulla recente Conferenza di Chicago della Società Americana di oncologia clinica (ASCO) - III Convegno nazionale della rete oncologica – SIFACT (Società italiana di farmacia clinica e terapia)** – 7-8 June 2019 – Centro Congressi SGR - Rimini, Italy
- 35) **Session Chair in New Drugs in Hematology** – 28 June 2019 – Palazzo Alabardieri, Napoli, Italy
- 36) **Gestione della tossicità delle nuove opzioni terapeutiche - Gruppo di miglioramento (FSC) Nuove prospettive nel campo della Leucemia Linfoblastica Acuta** – 4 July 2019, Hotel Baglioni, Firenze,
- 37) **President and Scientific Board in SOHO 1st Italian Conference, Session Chair in New Drugs in Acute Myeloid Leukemia (Session Chairs: C. Cerchione, H. Kantarjian) Talk: Environment-mediated drug resistance in AML; Session Chair in The near future of Multiple Myeloma and MGUS (Session Chairs: C. Cerchione, H. Lee) Talk: Multiple Myeloma: State of the art in Italy;** 25-26 September 2019, Crowne Plaza St. Peter's, Roma:
- 38) **Focus sulla malattia di Gaucher – I Master in Ematologia Pediatrica (Presidente e Responsabile Scientifico)** – 5 October 2019, Osp. Pausilipon, Napoli,
- 39) **Prima linea terapeutica nel Mieloma Multiplo - Post ASCO-ESMO 2019** – 11-12 October 2019, Rocca delle Caminate, Meldola (FC)
- 40) **Hematologic Malignancies, Chair in Multiple Myeloma Session** – 17-18 October 2019, Hotel Savoia, Rimini

- 41) **L'ematologia, l'oncologia e la medicina del dolore tra umanizzazione delle cure e precision medicine** – 24-25 October 2019, Napoli,
- 42) **Advisory Board ReMMMap, IQVIA** – 30 October 2019, IQVIA, Milano
- 43) **Italian Investigator meeting Avalon Trial** – 5 November 2019, Hotel Michelangelo, Milano,
- 44) **Carfilzomib-Lenalidomide-Dexamethasone in the management of Lenalidomide-refractory Multiple Myeloma - Under40 in Hematology** – 7-8 November 2019, Hotel Ramada, Milano,
- 45) **Pomalidomide-Dexamethasone in the management of heavily pretreated Multiple Myeloma - Under40 in Hematology** – 7-8 November 2019, Hotel Ramada, Milano,
- 46) **CAR-T nelle neoplasie ematologiche – Stato dell'arte: il futuro è oggi – I Master in Ematologia Pediatrica (Presidente e Responsabile Scientifico)** – 9 November 2019, Osp. Pausilipon, Napoli
- 47) **Il futuro dell'oncoematologia pediatrica– I Master in Ematologia Pediatrica (Presidente e Responsabile Scientifico)** – 9 November 2019, Osp. Pausilipon, Napoli,
- 48) **Advisory Board – Myelodysplastic Syndromes (MDS) Advisor Channel** – 11-13 November 2019,
- 49) **Multiple Myeloma: State of the art in Italy - A night with the hematologists** – 12 November 2019, Sala Tison IRST, Meldola (FC)
- 50) **Theapeutic approaches in LLA: How to integrate Inotuzumab in the current paradigm? Reuniao Anual Sociedade Portuguesa de Hematologia** – 14-15-16 November 2019, Altice Forum, Braga, Portugal
- 51) **AIL Pazienti Leucemia Mieloide Acuta** – Seminario Pazienti – Medici, 23 November 2019, Hotel Uappala, Pesaro,
- 52) **Esperienze cliniche e confronto “How I treat” - Leucemia Linfoblastica acuta: Sfide della real life** – 26 November 2019, Bianca Maria Palace Hotel – Milano
- 53) **Chair and Speaker (Multiple Myeloma: State of the art in Europe + Theapeutic approaches in LLA: How to integrate Inotuzumab in the current paradigm?) Third Annual European Global Summit on Hematological Malignancies** – 13-15 February 2020, Lisbon, Portugal
- 54) **Advisory Board “Belantamab Mafodotin: dati DREAMM-2”** – 14 May 2020, Virtual
- 55) **Advisory Board “Algoritmi di trattamento nel MMRR: temi di pratica clinica e subset di pazienti”** – IQVIA – 10 July 2020, Virtual
- 56) **Chair in Acute Lymphoblastic Leukemia – State of the art - 2nd SOHO Italian Conference** – A.Roma Lifestyle Hotel – 22-24 September 2020
- 57) **Chair in Acute Lymphoblastic Leukemia – Beyond ALL and near future - 2nd SOHO Italian Conference** – A.Roma Lifestyle Hotel – 22-24 September 2020
- 58) **Chair in Selected Oral Presentations - 2nd SOHO Italian Conference** – A.Roma Lifestyle Hotel – 22-24 September 2020

- 59) **Long term data from Pivotal Trials - CPX-351 in High Risk AML: from bench to bedside - JAZZ Pharmaceuticals Lunch Symposium-** 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
- 60) **Environment-mediated drug resistance in AML** - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
- 61) **Chair (with M.V. Mateos) in Multiple Myeloma – Hot topics in novel agents era** - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
- 62) **Chair (with K.C. Anderson) in Multiple Myeloma – State of the art** - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
- 63) **Multiple Myeloma – State of the art in Europe-** 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
- 64) **Case based discussion: Introducing Inotuzumab in day to day practice – 9th Annual Acute Leukemia Meeting** - 23-26 September 2020, Virtual
- 65) **Janssen CAR-T Referral Centre Physician Advisory Board October 2020** – 14 October 2020, Virtual
- 66) **PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE (Oral Communication)** – SIES XVI – Napoli – 15-17 October 2020
- 67) **Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma: old/new in novel agents'era.** XIth Eurasian Hematology Oncology Congress (EHOC) 2020 – 21-24 October 2020 – Virtual
- 68) **La terapia del Mieloma Multiplo recidivato/refrattario** – Nuove sfide in Ematologia – 26-28 October 2020, Virtual
- 69) **Overcoming Environment-Mediated Drug Resistance in AML** – 29-30 October 2020 - EUROLEUK 2020 – Virtual
- 70) **Advisory Board Virtuale - WEB MEETING - EMILIA ROMAGNA, 11 November 2020 - Mieloma Multiplo** 11 November 2020, Virtual
- 71) **La malattia minima residua** - Italian Leukemia Summit – 27-28 November 2020, Virtual
- 72) **Advisory Board – Il senso delle parole – Un'altra comunicazione è possibile** – 1 December 2020, Virtual
- 73) **Present and future of management of relapsed/refractory Multiple Myeloma +** Responsabile Scientifico - 1st SOHO Italy Clinical and Biological School of Multiple Myeloma – 15-16-17 December 2020, Virtual
- 74) **Report studio AVALON** – Nuovi approcci terapeutici nella leucemia mieloide acuta – ACCMED - 17 December 2020 – Virtual

- 75) **The frequency of monitoring during TFR - Discutendo di leucemia mieloide cronica, dalla strategia terapeutica alla comunicazione scientifica 3.0** 10/03/2021 – Virtual Conference
- 76) **1st SOHO Italy School of Acute Leukemia – Clinical and Biological - Presidente, Scientific Committee, Speaker and Chair (Talk: Environment mediated drug resistance in AML)** – 15-16-17/03/2021
- 77) **Bite bispecific T cell engager: a “new kid in town”– Virtual Conference Multiple Myeloma -** 29/03/2021 – IRST IRCCS Meldola (FC),
- 78) **FISH e citogenetica - Sardinian Myeloma Academy** 21/05/2021 – Virtual Conference;
- 79) **CASES Europe Insights Into AML** 21/05/2021 – Virtual conference;
- 80) **How I manage Multiple Myeloma in 2021 - Post COMy-TianQingHematology IMiDs Summit Forum** – 16/06/2021 Cina – Virtual Conference;
- 81) **Multilab: riflessioni sulle principali esperienze cliniche condivise nei workshop “Clinical practice sul Mieloma Multiplo” + Praticamente Ixazomib: presentazione e discussione di casi clinici interattivi** 17/06/2021 – Virtual Conference;
- 82) **Approcci terapeutici nel Mieloma Multiplo - Mieloma Multiplo: dalla diagnosi alla valutazione della malattia minima residua** 17/06/2021 – Virtual Conference;
- 83) **Progetto Il senso delle parole** - Luglio 2021
- 84) **Extracellular vesicles and their role in patients with Multiple Myeloma - Presidente, Scientific Committee, Speaker and Chair (Talk: How I manage relapsed/refractory Multiple Myeloma)** 01/07/2021 – Virtual Conference:
- 85) **Pratica Clinica MM Open Discussion** 02/09/2021 – 03/11/2021 – Virtual Project
- 86) **La carenza di ferro: esperti a confronto sulla best practice - Il ruolo della terapia marziale nel trattamento delle patologie oncoematologiche: stato dell’arte** 16-17/09/2021 Bussolengo (VR):
- 87) **3rd SOHO Italy Annual Conference – Presidente, Scientific Committee, Speaker and Chair (Talks: How I treat relapsed/refractory Multiple Myeloma in Europe; Multiple Myeloma: State of the art in Europe; New frontiers in overcoming; Environment-Mediated Drug Resistance in AML)** - 27-30/09/2021 - Roma

Papers:

- 1) **Cerchione C, Fabbricini R, Pane F, Luciano L.**
Vitiligo-like lesions in an adult patient treated with Imatinib Mesylate
Leuk Res.2009 Aug; 33(8): e104-5.

- 2) Pane F, Quintarelli F, Esposito N, Izzo B, De Angelis B, Peluso A, Muccioli Casadei G, Cosenza M, **Cerchione C**, Camera A, Luciano L.
Acute and Chronic Ph⁺ Leukemias: differential leukemogenesis pathways translate into different clinical needs
Hematologica, Vol.94, October 2009.
- 3) **Cerchione C**, Catalano L, Cerciello G, Avilia S, Picardi M, Risitano AM, Pisano I, Alfinito F, Pane F.
Role of Lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA)
Ann Hematol. 2015 Mar; 94(3): 531-4.
- 4) **Cerchione C**, Catalano L, Pareto AE, Picardi M, Pane F.
Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience
Support Care Cancer. 2015 Feb; 23(2): 301-2.
- 5) Fonti R, Pace L, **Cerchione C**, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S.
18-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with Multiple Myeloma: a comparative study
Clin Nucl Med 2015 Apr; 40(4): 303-8
- 6) **Cerchione C**, Lucignano M, Pane F, Catalano L.
Salvage therapy with pegylated liposomal doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.
Eur J Haematol. 2016 May; 96(5): 544.
- 7) Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, Migliaccio I, Picardi M, Pane F.
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
Support Care Cancer. 2016 Dec; 24(12): 4835-4837.
- 8) **Cerchione C**, De Renzo A, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M.
Pegfilgrastim in primary prophylaxis of febrile neutropenia following front-line bendamustine plus rituximab treatment in patients with indolent non Hodgkin lymphoma: a single center, real-life experience
Support Care Cancer. 2017 Mar; 25(3): 839-845.
- 9) **Cerchione C**, Nappi D, Di Perna M, Zacheo I, Pareto AE, Picardi M, Catalano L, Pane F.
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a patient with relapsed/refractory multiple myeloma
Case Rep Hematol. 2016; 2016: 6745286.
- 10) **Cerchione C**, Cerciello G, Avilia S, Della Pepa R, Pugliese N, Picardi M, Pane F, Catalano L.
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease
Blood Transfus. 2016 Oct 24; 1-4.
- 11) Della Pepa R, Pagano L, **Cerchione C**, Pugliese N, Pane F, Picardi M.
Reply to the letter to the editor "chronic disseminated candidiasis" by Kenneth Rolston
Support Care Cancer. 2017 Apr; 25(4): 1045-1046.
- 12) Pugliese N, Di Perna M, Cozzolino I, Ciancia G, Pettinato G, Zeppa P, Varone V, Masone S, **Cerchione C**, Della Pepa R, Simeone L, Salvatore C, Pane F, Picardi M.
Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma
Ann Hematol. 2017 Apr; 96(4): 627-637.
- 13) **Cerchione C**, Peluso I, Nappi D, Pareto AE, Picardi M, Martinelli V, Pane F.
Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis
Ann Hematol. 2017 Apr; 96(4): 697-699.
- 14) **Cerchione C**, Nappi D, Di Perna M, Zacheo I, Migliaccio I, Salvatore D, Picardi M, Pane F, Catalano L.

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide

Clinical Case reports, Vol 5, Issue 4, April 2017 Pages 505-507.

- 15) **Cerchione C**, Maraolo AE, Marano L, Pugliese N, Nappi D, Tosone G, Cimmino I, Cozzolino I, Martinelli V, Pane F, Picardi M.
Secondary syphilis mimicking malignancy: A case report and review of literature
J Infect Chemother. 2017 Aug; 23(8): 576-578.
- 16) Pugliese N, Salvatore P, Iula VD, Catania MR, Chiurazzi F, Della Pepa R, **Cerchione C**, Raimondo M, Giordano C, Simeone L, Caruso S, Pane F, Picardi M.
Ultrasonography-driven tigecycline-based antibiotic therapy significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia
Cancer Med. 2017. Jul; 6(7): 1500-1511.
- 17) Fiore M, Maraolo AE, Chiodini P, **Cerchione C**, Gentile I, Borgia G, Pace MC.
Is anticoagulation with novel oral anticoagulants an effective treatment for tuberculosis patients not achieving a therapeutic range with vitamin k antagonists? A Systematic Review.
Cardiovasc Hematol Disord Drug Targets. 2017; 17(2): 105-110.
- 18) Della Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, **Cerchione C**, Raimondo M, Di Perna M, Troncone G, Ciancia G, Intrieri M, Pane F.
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma
Br J Haematol. 2017 Jul 24.
- 19) Mondello P, Steiner N, Willenbacher W, **Cerchione C**, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M.
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Oncologist. 2018 Jan 9.
- 20) Romano A, Laura Parrinello N, **Cerchione C**, Letizia Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Alberto Palumbo G.
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.
Blood Cancer J. 2017 Dec 15; 7(12): 649.
- 21) Romano A, **Cerchione C**, Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Palumbo G
The neutrophil-lymphocyte ratio (NLR) and the lymphocyte-monocyte ratio (LMR) predict progression free survival in patients with newly diagnosed multiple myeloma treated upfront with novel agents
Blood Cancer J. 2017 Dec 15; 7(12): 649.
- 22) **Cerchione C**, Nappi D, Pareto AE, Romano A, Picardi M, Pane F, Catalano L
Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience
Anticancer Drugs. 2018 Feb 7.
- 23) Della Pepa R, **Cerchione C**, Pugliese N, Colicchio R, Salvatore P, Sirignano C, Soscia E, Pagano L, Sanguinetti M, Pane F, Picardi M.
Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on role of 1,3-beta-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography
Support Care Cancer. 2018 Mar 9.
- 24) **Cerchione C**, Nappi D, Pareto AE, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L
Safety and comfort of domestic bortezomib injection in real life experience
Support Care Cancer 2018 Mar 24.
- 25) **Cerchione C**, De Renzo A, Nappi D, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M.
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.
Support Care Cancer 2019 Jan 23.

- 26) Picardi M, Della Pepa R, **Cerchione C**, Pugliese N, Mortaruolo C, Trastulli F, Giordano C, Grimaldi F, Zacheo I, Raimondo M, Chiurazzi F, Pane F.
A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison.
Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):e184-e194. doi: 10.1016/j.clml.2018.12.008. Epub 2018 Dec 20.
- 27) Pugliese N, Giordano C, Nappi D, Luciano L, **Cerchione C**, Annunziata M, Casale B, Crisà E, Villa MR, Pezzullo L, Iovine M, Picardi M, Grimaldi F, Pane F, Martinelli V.
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Cancer Med. 2019 Jun;8(6):2802-2809. doi: 10.1002/cam4.2147. Epub 2019 Apr 17.
- 28) Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, **Cerchione C**, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U.
CAR-T cell therapy: a potential new strategy against prostate cancer.
J Immunother Cancer. 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7. Review.
- 29) **Cerchione C**, Martinelli G, Pedatella S, De Nisco M, Pugliese N, Manfra M, Marra N, Ronconi S, De Giorgi U, Altini M, Simonetti G, Di Rorà AGL, Bravaccini S, Catalano L, Dora Iula V, Pagano F, Picardi M, Bolognese A, Pane F, Martinelli V.
An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia.
Anticancer Drugs. 2020 Jan;31(1):67-72. doi: 10.1097/CAD.0000000000000850;
- 30) **Claudio Cerchione**, Giovanni Martinelli, Marco Picardi, Novella Pugliese, Davide Nappi, Aniello Casoria, Angela Gravetti, Delia Cangini, Maria Benedetta Giannini, Sonia Ronconi, Giorgia Simonetti, Andrea Ghelli Luserna Di Rorà, Ugo De Giorgi, Mattia Altini, Sara Bravaccini, Ilaria Santoriello, Cristiano Minucci, Fabrizio Pane and Vincenzo Martinelli.
Combined oral fentanyl citrate and midazolam as premedication for bone marrow aspiration and biopsy in patients with hematological malignancies: a randomized, controlled and patient-blinded clinical trial
J Clin Med. 2020 Feb 1;9(2):395. doi: 10.3390/jcm9020395.
- 31) Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonielli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, **Cerchione C**, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringham S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica. 2020 Feb 27;haematol.2019.241513. doi: 10.3324/haematol.2019.241513. Online ahead of print.
- 32) Mondello P, Musolino C, Dogliotti I, Bohn JP, Cavallo F, Ferrero S, Botto B, **Cerchione C**, Nappi D, De Lorenzo S, Martinelli G, Wolf D, Schmitt C, Loseto G, Cuzzocrea S, Willenbacher W, Mian M, Straus DJ
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.
Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25871. Online ahead of print.
- 33) Lucchesi A, Silimbani P, Musuraca G, Cerchione C, Martinelli G, Di Carlo P, Napolitano M.
Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.
J Med Virol. 2020 Jun 24;10.1002/jmv.26217. doi: 10.1002/jmv.26217. Online ahead of print.
- 34) Palmieri S, Rocco S, Vitagliano O, Catalano L, **Cerchione C**, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F.
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
Ann Hematol. 2020 Jun 25. doi: 10.1007/s00277-020-04158-4. Online ahead of print.
- 35) Nolan S, Vignali M, Klinger M, Dines JN, Kaplan IM, Svejnova E, Craft T, Boland K, Pesesky M, Gittelman RM, Snyder TM, Gooley CJ, Semprini S, **Cerchione C**, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Sambri V, Martinelli G, Goldman JD, Heath JR, Notarangelo LD, Carlson JM, Martinez-Lopez J, Robins HS.
A large-scale database of T-cell receptor beta (TCR β) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2.

- 36) Snyder TM, Gittelman RM, Klinger M, May DH, Osborne EJ, Taniguchi R, Zahid HJ, Kaplan IM, Dines JN, Noakes MN, Pandya R, Chen X, Elasady S, Svejnoha E, Ebert P, Pesesky MW, De Almeida P, O'Donnell H, DeGottardi Q, Keitany G, Lu J, Vong A, Elyanow R, Fields P, Greissl J, Baldo L, Semprini S, **Cerchione C**, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Imberti L, Sottini A, Quiros-Roldan E, Rossi C, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Tompkins MF, Alba C, Dalgard C, Sambri V, Martinelli G, Goldman JD, Heath JR, Su HC, Notarangelo LD, Martinez-Lopez J, Carlson JM, Robins HS.
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels.
medRxiv. 2020 Aug 4;2020.07.31.20165647. doi: 10.1101/2020.07.31.20165647. Preprint.
- 37) **Cerchione C**, Nappi D, Musuraca G, Lucchesi A, Cimmino I, Pane F, De Renzo A, Martinelli G.
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.
Medicine (Baltimore). 2020 Aug 14;99(33):e21440. doi: 10.1097/MD.00000000000021440.
- 38) Bravaccini S, Martinelli G, **Cerchione C**.
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Cell Transplant. 2020 Jan-Dec;29:963689720950209. doi: 10.1177/0963689720950209.
- 39) Ricciuti G, Falcone AP, Cascavilla N, Martinelli G, **Cerchione C**.
Autologous stem cell transplantation in multiple myeloma.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04114-2. Online ahead of print.
- 40) Nagarajan C, Tan MS, Chen Y, Martinelli G, **Cerchione C**.
Current and future perspectives of maintenance therapy in multiple myeloma.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04117-8. Online ahead of print.
- 41) Chen Y, Nagarajan C, Tan MS, Martinelli G, **Cerchione C**.
BCMA-targeting approaches for treatment of multiple myeloma.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04121-X. Online ahead of print.
- 42) Derudas D, Capraro F, Martinelli G, **Cerchione C**.
Old and new generation immunomodulatory drugs in multiple myeloma.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04125-7. Online ahead of print.
- 43) Santoro M, Romano A, Mancuso S, Siragusa S, Di Raimondo F, Martinelli G, **Cerchione C**.
Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04133-6. Online ahead of print.
- 44) Romano A, Santoro M, Conticello C, Siragusa S, Di Raimondo F, Martinelli G, **Cerchione C**.
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04141-5. Online ahead of print.
- 45) Martino M, Paviglianiti A, Gentile M, Martinelli G, **Cerchione C**.
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04142-7. Online ahead of print.
- 46) Gentile M, Morabito F, Martino M, Vigna E, Martino EA, Mendicino F, Martinelli G, **Cerchione C**.
Chemotherapy-based regimens in multiple myeloma in 2020.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04145-2. Online ahead of print.
- 47) Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, Martín-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, **Cerchione C**.
CAR T cells targeting options in the fight against multiple myeloma.
Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04146-4. Online ahead of print.
- 48) Vozella F, Fazio F, Lapietra G, Petrucci MT, Martinelli G, **Cerchione C**.
Monoclonal antibodies in multiple myeloma.

Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04149-X. Online ahead of print.

- 49) Mosquera Orgueira A, Bao Pérez L, Mosquera Torre A, Peleteiro Ráindo A, Cid López M, Diaz Arias JA, Ferreiro Ferro R, Antelo Rodríguez B, González Pérez MS, Albors Ferreiro M, Alonso Vence N, Pérez Encinas MM, Bello López JL, Martinelli G, **Cerchione C.**
FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.06989-X. Online ahead of print.
- 50) Abdul-Hamil NA, Wong GC, Nagarajan C, Martinelli G, **Cerchione C.**
Midostaurin in acute myeloid leukemia: review of current evidence and practical considerations in routine clinical use.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07014-7. Online ahead of print.
- 51) Palmieri R, Buccisano F, Maurillo L, Del Principe MI, Paterno G, Venditti A, Martinelli G, **Cerchione C.**
Current strategies for detection and approach to measurable residual disease in Acute Myeloid Leukemia.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07016-0. Online ahead of print.
- 52) Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, Simonetti G, Martinelli G, **Cerchione C.**
CPX-351 - Daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07017-2. Online ahead of print.
- 53) Cangini D, Silimbani P, Cafaro A, Giannini MB, Masini C, Ghelli Luserna Di Rorà A, Simonetti G, Martinelli G, **Cerchione C.**
Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07018-4. Online ahead of print.
- 54) Gottardi M, Sperotto A, Ghelli Luserna Di Rorà A, Padella A, Cangini D, Giannini MB, Simonetti G, Martinelli G, **Cerchione C.**
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07019-6. Online ahead of print.
- 55) Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, **Cerchione C.**
Enasidenib and Ivosidenib in AML.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07024-X. Online ahead of print.
- 56) Lanza F, Maffini E, Saraceni F, Massari E, Rondoni M, Daghia G, Olivieri A, **Cerchione C** and Martinelli G.
New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07031-7. Online ahead of print.
- 57) **Cerchione C**, Martinelli G.
Acute leukemias in 2020: state of the art.
Minerva Med. 2020 Sep 22. doi: 10.23736/S0026-4806.20.07049-4. Online ahead of print.
- 58) Montefusco V, Mussetti A, Sala MR, Martinelli G, **Cerchione C.**
Old and new generation proteasome inhibitors in multiple myeloma.
Panminerva Med. 2020 Sep 22. doi: 10.23736/S0031-0808.20.04148-8. Online ahead of print.
- 59) **Cerchione C**, Martinelli G.
Multiple myeloma in 2020: state of the art.
Panminerva Med. 2020 Sep 22. doi: 10.23736/S0031-0808.20.04159-2. Online ahead of print.
- 60) Ghelli Luserna di Rorà A, **Cerchione C**, Martinelli G, Simonetti G.
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
J Hematol Oncol. 2020 Sep 21;13(1):126. doi: 10.1186/s13045-020-00959-2.
- 61) Molica M, Noguera NI, Trawinska MM, Martinelli G, **Cerchione C** and Abruzzese E.
Treatment free remission in chronic myeloid leukemia: Lights and shadows.
Hematol Rep. 2020 Sep 21;12(Suppl 1):8950. doi: 10.4081/hr.2020.8950. eCollection 2020 Sep 21.
- 62) Romano A, **Cerchione C**, Conticello C, Martinelli G, Di Raimondo F.
How we manage smoldering multiple myeloma.
Hematol Rep. 2020 Sep 21;12(Suppl 1):8951. doi: 10.4081/hr.2020.8951. eCollection 2020 Sep 21.

- 63) Montefusco V, Martinelli G, **Cerchione C**.
How I manage frontline transplant-eligible multiple myeloma in Italy.
Hematol Rep. 2020 Sep 21;12(Suppl 1):8954. doi: 10.4081/hr.2020.8954. eCollection 2020 Sep 21.
- 64) Lee HC, **Cerchione C**.
How I treat relapsed and/or refractory multiple myeloma.
Hematol Rep. 2020 Sep 21;12(Suppl 1):8955. doi: 10.4081/hr.2020.8955. eCollection 2020 Sep 21.
- 65) Derudas D, Capraro F, Martinelli G, **Cerchione C**.
How I manage frontline transplant-ineligible multiple myeloma.
Hematol Rep. 2020 Sep 21;12(Suppl 1):8956. doi: 10.4081/hr.2020.8956. eCollection 2020 Sep 21.
- 66) Ravaioli S, Tebaldi M, Fonzi E, Angeli D, Mazza M, Nicolini F, Lucchesi A, Fanini F, Pirini F, Tumedei MM, **Cerchione C**, Viale P, Sambri V, Martinelli G, Bravaccini S.
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients.
Cell Transplant. 2020 Jan-Dec;29:963689720968749. doi: 10.1177/0963689720968749.
- 67) Martino M, Paviglianiti A, Memoli M, Martinelli G, **Cerchione C**,
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
Front. Oncol. | doi: 10.3389/fonc.2020.592487
- 68) Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, **Cerchione C**, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O
Hydroxychloroquine as prophylaxis for COVID-19: a review
Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020.
- 69) Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, **Cerchione C**.
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
- 70) Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, **Cerchione C**.
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Int J Mol Sci. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150.
- 71) Cimmino I, Bravaccini S, **Cerchione C**.
Urinary Biomarkers in Tumors: An Overview.
Methods Mol Biol. 2021;2292:3-15. doi: 10.1007/978-1-0716-1354-2_1.
- 72) Kaufman GP, **Cerchione C**.
Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.
Front Oncol. 2021 Feb 3;10:624573. doi: 10.3389/fonc.2020.624573. eCollection 2020.
- 73) Matteucci F, Paganelli G, Martinelli G, **Cerchione C**.
PET/CT in Multiple Myeloma: Beyond FDG.
Front Oncol. 2021 Jan 25;10:622501. doi: 10.3389/fonc.2020.622501. eCollection 2020.
- 74) Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, **Cerchione C**, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, Bello López JL.
Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
PLoS One. 2021 Feb 16;16(2):e0247093. doi: 10.1371/journal.pone.0247093. eCollection 2021.
- 75) Bolli N, Martinelli G, **Cerchione C**.
The molecular pathogenesis of multiple myeloma.
Hematol Rep. 2020 Dec 18;12(3):9054. doi: 10.4081/hr.2020.9054. eCollection 2020 Dec 2.
PMID: 33408844 Free PMC article.
- 76) Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, **Cerchione C**, Martinelli G, Malavasi F, Lanza F.
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.

Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.

- 77) Rossi A, Prochowski Iamurri A, **Cerchione C**, Gentili N, Danesi V, Altini M, Paganelli G, Barone D. Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic. Insights Imaging. 2020 Dec 3;11(1):129. doi: 10.1186/s13244-020-00935-x.
- 78) Martino M, Paviglianiti A, Memoli M, Martinelli G, **Cerchione C**. **Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.** Front Oncol. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. eCollection 2020.
- 79) Picardi M, Giordano C, Della Pepa R, **Cerchione C**, Pugliese N, Leone A, Vitiello S, Pane F. **Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma.** Eur J Haematol. 2020; 105: 667-671". Eur J Haematol. 2020 Nov 30. doi: 10.1111/ejh.13558. Online ahead of print.
- 80) Martino M, Paviglianiti A, Memoli M, Martinelli G, **Cerchione C**. **Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.** Front Oncol. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. eCollection 2020.
- 81) Rossi A, Prochowski Iamurri A, **Cerchione C**, Gentili N, Danesi V, Altini M, Paganelli G, Barone D. **Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic.** Insights Imaging. 2020 Dec 3;11(1):129. doi: 10.1186/s13244-020-00935-x. PMID: 33270166 Free PMC article. Review.
- 82) Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, **Cerchione C**, Martinelli G, Malavasi F, Lanza F. **Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.** Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.
- 83) Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, **Cerchione C**, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O. **Hydroxychloroquine as Prophylaxis for COVID-19: A Review.** Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020.
- 84) Bolli N, Martinelli G, **Cerchione C**. **The molecular pathogenesis of multiple myeloma.** Hematol Rep. 2020 Dec 18;12(3):9054. doi: 10.4081/hr.2020.9054. eCollection 2020 Dec 2.
- 85) Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreira Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, **Cerchione C**, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, Bello López JL. **Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.** PLoS One. 2021 Feb 16;16(2):e0247093. doi: 10.1371/journal.pone.0247093. eCollection 2021. PMID: 33592069 Free PMC article.
- 86) Matteucci F, Paganelli G, Martinelli G, **Cerchione C**. **PET/CT in Multiple Myeloma: Beyond FDG.** Front Oncol. 2021 Jan 25;10:622501. doi: 10.3389/fonc.2020.622501. eCollection 2020.
- 87) Kaufman GP, **Cerchione C**. **Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.** Front Oncol. 2021 Feb 3;10:624573. doi: 10.3389/fonc.2020.624573. eCollection 2020. PMID: 33614504 Free PMC article. Review.
- 88) Cimmino I, Bravaccini S, **Cerchione C**. **Urinary Biomarkers in Tumors: An Overview.** Methods Mol Biol. 2021;2292:3-15. doi: 10.1007/978-1-0716-1354-2_1.
- 89) Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, **Cerchione C**. **A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.** Int J Mol Sci. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150.

PMID: 33670075 Free PMC article. Review.

- 90) Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, **Cerchione C**.
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
- 91) **Cerchione C**, Locatelli F, Martinelli G.
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Front Oncol. 2021 Mar 25;11:632231. doi: 10.3389/fonc.2021.632231. eCollection 2021.
PMID: 33842339 Free PMC article. Review.
- 92) Marconi G, Giannini MB, Bagnato G, Simonetti G, **Cerchione C**, Mosquera Orgueira A, Musuraca G, Martinelli G.
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
Expert Opin Drug Saf. 2021 Apr 14:1-9. doi: 10.1080/14740338.2021.1913120.
- 93) Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Díaz Arias JÁ, González Pérez MS, Antelo Rodríguez B, Alonso Vence N, Bao Pérez L, Ferreiro Ferro R, Albors Ferreiro M, Abuín Blanco A, Fontanes Trabazo E, **Cerchione C**, Martinelli G, Montesinos Fernández P, Mateo Pérez Encinas M, Luis Bello López J.
Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling.
Front Oncol. 2021 Mar 29;11:657191. doi: 10.3389/fonc.2021.657191. eCollection 2021.
- 94) **Cerchione C**, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H.
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.
Front Oncol. 2021 Mar 29;11:639387. doi: 10.3389/fonc.2021.639387. eCollection 2021.
- 95) Picardi M, Cavaliere C, Della Pepa R, Nicolai E, Soricelli A, Giordano C, Pugliese N, Rascato MG, Cappuccio I, Campagna G, **Cerchione C**, Vigliar E, Troncone G, Mascolo M, Franzese M, Castaldo R, Salvatore M, Pane F
PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.
Ann Hematol. 2021 Jun;100(6):1525-1535. doi: 10.1007/s00277-021-04537-5. Epub 2021 Apr 28.
- 96) Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, **Cerchione C**, Martinelli G, Morabito F, Di Raimondo F, Gentile M.
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.
Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021.
- 97) **Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.**
Cerchione C, Nappi D, Martinelli G.
Support Care Cancer. 2021 May 14. doi: 10.1007/s00520-021-06266-x. Online ahead of print.
PMID: 33990881 Review.
- 98) Isidori A, **Cerchione C**, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A.
Immunotherapy in Acute Myeloid Leukemia: Where We Stand.
Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021.
PMID: 34041025 Free PMC article. Review.
- 99) Martino M, Canale FA, Alati C, Vincelli ID, Moscato T, Porto G, Loteta B, Naso V, Mazza M, Nicolini F, Ghelli Luserna di Rorà A, Simonetti G, Ronconi S, Ceccolini M, Musuraca G, Martinelli G, **Cerchione C**.
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.
Cancers (Basel). 2021 May 27;13(11):2639. doi: 10.3390/cancers13112639.
PMID: 34072068 Free PMC article. Review.
- 100) Simonetti G, Angeli D, Petracci E, Fonzi E, Vedovato S, Sperotto A, Padella A, Ghetti M, Ferrari A, Robustelli V, Di Liddo R, Conconi MT, Papayannidis C, **Cerchione C**, Rondoni M, Astolfi A, Ottaviani E, Martinelli G, Gottardi M.
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia.
Front Oncol. 2021 Jun 2;11:684396. doi: 10.3389/fonc.2021.684396. eCollection 2021.

PMID: 34150648 Free PMC article.

- 101) **Cerchione C**, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao Pérez L, Marconi G, Isidori A, Pérez Encinas MM, Martinelli G.
Safety of FLT3 inhibitors in patients with acute myeloid leukemia.
Expert Rev Hematol. 2021 Sep;14(9):851-865. doi: 10.1080/17474086.2021.1969911. Epub 2021 Aug 30.
PMID: 34424108
- 102) Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, **Cerchione C**, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G.
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Cell Biol Toxicol. 2021 Sep 14. doi: 10.1007/s10565-021-09640-x. Online ahead of print. PMID: 34519926
- 103) Gottardi M, Simonetti G, Sperotto A, Nappi D, Ghelli Luserna di Rorà A, Padella A, Norata M, Giannini MB, Musuraca G, Lanza F, **Cerchione C**, Martinelli G.
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
Cancers (Basel). 2021 Sep 11;13(18):4566. doi: 10.3390/cancers13184566. PMID: 34572794 Free article. Review.

Abstracts/Poster presentations in national/international events:

- 1) Luciano L, **Cerchione C**, Becchimanzi C, Pane F, Rotoli B.
"Imatinib Mesylate and Cardiac function"
Haematologica Abstract Book, SIE, Vol. 92 supplement no.3, October 2007
- 2) V. Schiano Lomoriello, R. Esposito, R. Viceconti, **C. Cerchione**, L. Luciano, M. Galderisi
"L'Imatinib aumenta la massa ventricolare ed il diametro atriale sinistro nei pazienti affetti da leucemia mieloide cronica"
Giornale Italiano di Cardiologia volume 9, Suppl.2 al n.5 May 2008
- 3) Olim P, Sousa P, Carda J, Sousa M.I., Tavares P, **Cerchione C**
"Linfoma osseo primario – a experiencia de uma instituicao"
Abstract Congresso Nazionale Società Portoghese di Ematologia September 2008
- 4) Luciano L, **Cerchione C**, Schiano Lomoriello V, Esposito R, Fabbricini R, Galderisi M, Pane F, Rotoli B
"Effect of Imatinib Mesylate on cardiac function"
Haematologica Abstract Book, SIES, Vol. 93 supplement no.2, September 2008
- 5) Caliendo I, Luciano L, Danise P, Rivellini F, De Vita B, Guerriero A, **Cerchione C**, Tafuri A, Clemente L, Ingenito M, D'Arco A
"Progression of a myelodysplastic syndrome, with nonrandom aneuploidy of chromosome 21, to acute myeloid leukemia with t(9;15) (q22;q22) as the sole cytogenetic abnormality"
Haematologica Abstract Book, SIES, Vol. 93 supplement no.2, September 2008
- 6) Luciano L, **Cerchione C**, Ciancia R, Pane F
"Renal failure associated to tyrosine kinase inhibitors"
Haematologica Abstract Book, EHA, Vol. 95 supplement no.2, June 2010
- 7) Luciano L, **Cerchione C**, Ciancia R, Pane F
"Successful pregnancies in Chronic Myeloid Leukaemia male patient on Imatinib therapy"

- 8) **Cerchione C**, Luciano L, Cincia R, Pane F
"Renal failure associated to tyrosine kinase inhibitors"
 Abstract Book Riunione Annuale dei Centri di Ematologia Meridionale ed Insulare (SIE SUD), con Comunicazione Orale
- 9) **Cerchione C**, Luciano L, Cincia R, Pane F
"Successful pregnancies in Chronic Myeloid Leukaemia male patient on Imatinib therapy"
 Abstract Book Riunione Annuale dei Centri di Ematologia Meridionale ed Insulare (SIE SUD), con Comunicazione Orale
- 10) **Cerchione C**, Luciano L, Cincia R, Pane F
"LA PATERNITA' NEI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN TERAPIA CON GLI INIBITORI DELLE TIROSINCHINASI"
 Abstract Book Giornate Scientifiche "Bruno Rotoli" Federico II
- 11) **Cerchione C**, Luciano L, Cincia R, Pane F
"NEFROTOSSICITA' NEI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN TERAPIA CON GLI INIBITORI DELLE TIROSINCHINASI"
 Abstract Book Giornate Scientifiche "Bruno Rotoli" Federico II
- 12) Della Pepa R., Cacciapuoti V., Cerciello G., Avilia S., **Cerchione C.**, Luciano L., Alfinito F., Pane F.
"La tecnica FISH (Fluorescent In Situ Hybridization) è un ottimo strumento per migliorare la diagnosi delle Sindromi Mielodisplastiche Primarie (MDS)"^{SEP}
 Abstract Book Giornate Scientifiche "Bruno Rotoli" Federico II
- 13) **Cerchione C**, Cerciello G, Della Pepa R, Cincia R, Matarazzo M, Alfinito F, Pane F
"Combination of deferasirox and deferoxamine for management of iron overload in myelodysplastic syndromes in hepatopathic patient: A case report"
 Leukemia Research, Volume 35, Supplement 1, S1-S166 (May 2011)
- 14) Cerciello G, **Cerchione C**, Cosenza M, Luciano L, Alfinito F, Pane F, Risitano AM
"Myelodysplastic syndromes and pure red cell aplasia with del (5q)"
 Leukemia Research, Volume 35, Supplement 1, S1-S166 (May 2011)
- 15) **Cerchione C**, Cerciello G, Della Pepa R, Cincia R, Matarazzo M, Alfinito F, Pane F
"Safety and efficacy of combination therapy with Deferasirox and Deferoxamine for management of iron overload in multitransfused hepatopathic patient with myelodysplastic syndrome: a case report"
 Haematologica Abstract Book, EHA London, Vol. 96 supplement no.2, June 2011
- 16) Della Pepa R, **Cerchione C**, Cerciello G, Izzo B, Muccioli Casadei G, Alfinito F, Pane F
"Myelodysplastic syndromes with del(5q) and JAK2 V617F mutation: a case of hematologic response to Lenalidomide therapy"
 Haematologica Abstract Book, EHA London, Vol. 96 supplement no.2, June 2011
- 17) Pugliese N, Gravetti A, Quintarelli C, Madonna E, Izzo B, Muccioli Casadei G, **Cerchione C**, Martinelli V, Pane F
"Hydroxyurea plus Anagrelide combined therapy is more suitable than sequence schedule of the two drugs"
 Haematologica Abstract Book, EHA London, Vol. 96 supplement no.2, June 2011
- 18) Cincia R, **Cerchione C**, Seneca E, Beneduce G, Pisano I, Cacciapuoti V, Luciano L, Pane F
"Myelodysplastic/myeloproliferative neoplasm: a future therapeutic perspective"
 Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011
- 19) **Cerchione C**, Cerciello G, Della Pepa R, Avilia S, Cincia R, Matarazzo M, Alfinito F, Pane F
"Management of iron overload in myelodysplastic syndromes (MDS): combination of deferasirox and deferoxamine in a hepatopathic patient"
 Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011
- 20) Cerciello G, **Cerchione C**, Della Pepa R, Avilia S, Cosenza M, Luciano L, Alfinito F, Pane F, Risitano AM
"Pure red cell aplasia (PRCA) and myelodysplastic syndromes (MDS) with del (5q)"
 Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011
- 21) Della Pepa R, **Cerchione C**, Cerciello G, Avilia S, Izzo B, Muccioli Casadei G, Alfinito F, Pane F

- “Hematologic response to Lenalidomide in JAK2 V617F-positive essential thrombocytemia (TE) associated to del (5q) myelodysplastic syndrome: a case report”**
Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011
- 22) Luciano L, Seneca E, **Cerchione C**, Ciancia R, Pisano I, Cosenza M, Peluso AL, Pane F
“A particular mutational status in a chronic myeloid leukemia patient treated with different tyrosin-kinase inhibitors”
Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011
- 23) Pugliese N, Marano L, Gherghi M, Quintarelli C, De Angelis B, **Cerchione C**, Errichiello S, Muccioli Casadei G, Beneduce G, Martinelli V, Pane F
“Anagrelide in monotherapy or combined with hydroxyurea yields a high rate of complete response in Essential Thrombocythemia”
Haematologica Abstract Book, EHA Amsterdam, Vol.97 supplement no.1, June 2012
- 24) Pugliese N, Marano L, Picardi M, Gherghi M, Ciancia G, **Cerchione C**, Quintarelli C, Martinelli V, Pane F
“Spleen is the hidden hitch of Essential Thrombocythemia”
Haematologica Abstract Book, EHA Amsterdam, Vol.97 supplement no.1, June 2012
- 25) **Cerchione C**, Cerciello G, Della Pepa R, Matarazzo M, Alfinito F, Pane F
“Deferasirox and Deferoxamine combination therapy: a case of management of iron overload in Myelodysplastic Syndrome in an hepatopathic patient”
Haematologica Abstract Book, EHA Amsterdam, Vol.97 supplement no.1, June 2012
- 26) Cerchione C, Battipaglia G, Migliaccio I, Salvatore S, Camera A, Cerciello G, Della Pepa R, Chiurazzi F, Pane F
“Secondary hemophagocytic lymphohistiocytosis five years after acute myeloid leukemia: a case report”
Haematologica Abstract Book, Sies Roma, Vol.97 supplement no.2, October 2012
- 27) **Claudio Cerchione**, Fabrizio Pane, Marco Picardi
“Monitoraggio dei livelli plasmatici degli antimicotici azolici nei pazienti neutropenici e correlazioni con efficacia terapeutica ed effetti tossici”
Presentazione al Progetto Under40 in Hematology, Napoli 2012
- 28) **C. Cerchione**, V. Russo, F. Tucci, G. Loffredo, N. Marra, R. Parasole, F. Petruzzello, N. Crescenzo, G. Menna, V. Poggi
“La sindrome autoimmune linfoproliferativa (ALPS): Esperienza del nostro centro AIEOP”
Librone abstract XXXVIII Congresso nazionale AIEOP, Roma, Giugno 2013
- 29) **C. Cerchione**, V. Russo, F. Tucci, G. Loffredo, N. Marra, R. Parasole, F. Petruzzello, V. Poggi
“Un caso di PTT in età pediatrica”
Librone abstract XXXVIII Congresso nazionale AIEOP, Roma, Giugno 2013
- 30) **C. Cerchione**, G. Cerciello, R. Della Pepa, N. Pugliese, L. Marano, O. Vitagliano, M. Matarazzo, F. Pane, F. Alfinito
Hematology, University of Naples “Federico II”, Naples, Italy
“Combination of Deferasirox and Deferoxamine in management of iron overload in Myelodysplastic syndromes (MDS): an update in a hepatopathic patient”
MDS Foundation 2013, Berlin, Abstract Book Leukemia Research, supplement May 2013
- 31) **C. Cerchione**, G. Cerciello, R. Della Pepa, N. Pugliese, L. Marano, O. Vitagliano, L. Luciano, F. Alfinito, F. Pane, A.M. Risitano
Hematology, University of Naples “Federico II”, Naples, Italy
“Role of Lenalidomide in management of Pure Red Cell Aplasia (PRCA) and Myelodysplastic Syndromes (MDS) with del (5q)”
MDS Foundation 2013, Berlin, Abstract Book Leukemia Research, supplement May 2013
- 32) P. Danise, O. Vitagliano, **C. Cerchione**, I. Soriente, A.M. D’Arco, F. Pane, F. Alfinito
Hematology, University of Naples “Federico II”, Naples, Italy
“Erythropoietic aspects in MDS patients responders to ESAs treatment”
MDS Foundation 2013, Berlin, Abstract Book Leukemia Research, supplement May 2013
- 33) **Claudio Cerchione**, Emanuela Madonna, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano
BENDAMUSTINE: A NEW OPTION FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

- 34) **Claudio Cerchione**, Emanuela Madonna, Rossella Fabbicini, Luana Marano, Novella Pugliese, Fabrizio Pane, Lucio Catalano
A NEW OPPORTUNITY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CED)
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 35) **Claudio Cerchione**, Emanuela Madonna, Rossella Fabbicini, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano
TWENTY-FIVE MG LENALIDOMIDE EVERY OTHER DAY IN PATIENTS AFFECTED BY MULTIPLE MYELOMA AND RENAL FAILURE
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 36) **Claudio Cerchione**, Novella Pugliese, Luana Marano, Giuseppe Cerciello, Simona Avilia, Fabrizio Pane, Lucio Catalano
PEGFILGRASTIM AS PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING CHEMOTHERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 37) **Claudio Cerchione**, Emanuela Madonna, Rossella Fabbicini, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano
DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 38) Paolo Danise, **Claudio Cerchione**, Orsola Vitagliano, Ilaria Soriente, Alfonso Maria D'Arco, Fabrizio Pane, Fiorella Alfinito
ERYTHROPOIETIC ASPECTS IN MDS PATIENTS RESPONDERS TO ESAS TREATMENT
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 39) Fiorella Alfinito, Orsola Vitagliano, **Claudio Cerchione**, Giovanna Giagnuolo, Ilaria Soriente, Alfonso Maria D'Arco, Paolo Danise, Fabrizio Pane
ANALYSIS OF RESPONSE TO ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN 114 MYELOYDYSPLASTIC SYNDROME (MDS) PATIENTS FROM REGISTRO CAMPANO DELLE MIELODISPLASIE
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 40) Novella Pugliese, **Claudio Cerchione**, Francesco Grimaldi, Marta Raimondo, Maria Di Perna, Simona Pagliuca, Fabrizio Pane, Marco Picardi
BENDAMUSTINE-BASED THERAPY IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA.
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 41) Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Luana Marano, Santa Errichiello, **Claudio Cerchione**, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
THE INTERFERON SCORE TOWARDS PREDICTION OF RESPONSIVNESS TO INTERFERON ALPHA IN ESSENTIAL THROMBOCYTHEMIA
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 42) Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Maddalena Raia, **Claudio Cerchione**, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
ALL-TRANS RETINOIC ACID POTENTIATES THE INHIBITORY EFFECTS OF INTERFERON ALPHA (IFN) ON CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN) PROGENITORS IN VITRO.
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 43) Giovanna Giagnuolo, **Claudio Cerchione**, Piera Angelillo, Orsola Vitagliano, Novella Pugliese, Luana Marano, Giorgia Battipaglia, Simona Avilia, Fiorella Alfinito, Giuseppe Cerciello, Fabrizio Pane
BENEFITS OF THE USE OF AZACITIDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY
Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 44) **Claudio Cerchione**, Giuseppe Cerciello, Roberta Della Pepa, Novella Pugliese, Luana Marano, Orsola Vitagliano, Luigia Luciano, Fiorella Alfinito, Fabrizio Pane, Antonio Maria Risitano
ROLE OF LENALIDOMIDE IN MANAGEMENT OF MYELOYDYSPLASTIC SYNDROMES (MDS) WITH DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA)

- 45) **Claudio Cerchione**, Giuseppe Cerciello, Roberta Della Pepa, Novella Pugliese, Luana Marano, Orsola Vitagliano, Margherita Matarazzo, Fabrizio Pane, Fiorella Alfinito
COMBINATION OF DEFERASIROX AND DEFEROXAMINE IN MANAGEMENT OF IRON OVERLOAD IN MYELODYSPLASTIC SYNDROMES (MDS): AN UPDATE IN A HEPATOPATIC PATIENT
 Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 46) Giusi Barra, **Claudio Cerchione**, Emanuela Madonna, G.Pasquale, A.Sementa, Fabrizio Pane, Lucio Catalano, Raffaele De Palma
SPHINGOSINE KINASE 2 IS OVEREXPRESSED IN PATIENTS AFFECTED BY MULTIPLE MYELOMA
 Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013
- 47) **Claudio Cerchione**, Giovanna Giagnuolo, Piera Angelillo, Simona Avilia, Orsola Vitagliano, Novella Pugliese, Luana Marano, Anna Pareto, Fiorella Alfinito, Fabrizio Pane, Giuseppe Cerciello
BENEFITS OF THE USE OF AZACITIDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY
 XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book
- 48) Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Nicola Esposito, **Claudio Cerchione**, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
INTERFERON SIGNATURE PREDICTS RESPONSIVENESS IN ESSENTIAL THROMBOCYTHEMIA
 XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book
- 49) Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Maddalena Raia, **Claudio Cerchione**, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
IN VITRO SINERGISTIC INHIBITORY EFFECTS USING COMBINATION OF INTERFERON ALPHA AND ALL-TRANS RETINOIC ACID IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN)
 XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book
- 50) **Claudio Cerchione**, Emanuela Madonna, Luana Marano, Novella Pugliese, Elisa Seneca, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano
MANAGEMENT OF MULTIPLE MYELOMA WITH BENDAMUSTINE: A FURTHER OPTION FOR RELAPSED AND REFRACTORY PATIENTS
 XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book
- 51) **Claudio Cerchione**, Novella Pugliese, Luana Marano, Giuseppe Cerciello, Simona Avilia, Elisa Seneca, Fabrizio Pane, Lucio Catalano
PEGFILGRASTIM IN THE MANAGEMENT OF POSTCHEMOTHERAPY FEBRILE NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
 XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book
- 52) **Claudio Cerchione**, Paolo Danise, Orsola Vitagliano, Giuseppe Cerciello, Anna Pareto, Ilaria Soriente, Alfonso Maria D'Arco, Fabrizio Pane, Fiorella Alfinito
EVALUATION OF ERYTHROPOIETIC ASPECTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES RESPONDERS TO ERYTHROPOIESIS STIMULATING AGENTS (ESAs)
 XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book
- 53) **Claudio Cerchione**, Emanuela Madonna, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano
MANAGEMENT OF MULTIPLE MYELOMA WITH BENDAMUSTINE: A FURTHER OPTION FOR RELAPSED AND REFRACTORY PATIENTS
 Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 54) **Claudio Cerchione**, Novella Pugliese, Luana Marano, Giuseppe Cerciello, Simona Avilia, Elisa Seneca, Fabrizio Pane, Lucio Catalano

PEGFILGRASTIM IN THE MANAGEMENT OF POST-CHEMOTHERAPY FEBRILE NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

- 55) Paolo Danise, **Claudio Cerchione**, Orsola Vitagliano, Giuseppe Cerciello, Ilaria Soriente, Alfonso Maria D'Arco, Fabrizio Pane, Fiorella Alfinito
EVALUATION OF ERYTHROPOIETIC ASPECTS IN PATIENTS WITH MYELODISPLASTIC SYNDROMES RESPONDERS TO ERYTHROPOIESIS STIMULATING AGENTS
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 56) Fiorella Alfinito, **Claudio Cerchione**, Orsola Vitagliano, Giovanna Giagnuolo, Giuseppe Cerciello, Ilaria Soriente, Alfonso Maria D'Arco, Paolo Danise, Fabrizio Pane
ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 57) Novella Pugliese, **Claudio Cerchione**, Francesco Grimaldi, Marta Raimondo, Maria Di Perna, Simona Pagliuca, Fabrizio Pane, Marco Picardi
EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMEN IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA.
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 58) Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Luana Marano, Santa Errichiello, Nicola Esposito, **Claudio Cerchione**, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
GENE EXPRESSION DRIVES INTERFERON TAILORED THERAPY IN ESSENTIAL THROMBOCYTHEMIA
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 59) Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Maddalena Raia, **Claudio Cerchione**, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
SINERGISTIC INTERACTION BETWEEN ALL-TRANS RETINOIC ACID AND INTERFERON ALPHA IN VITRO MODEL OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN)
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 60) **Claudio Cerchione**, Giuseppe Cerciello, Roberta Della Pepa, Novella Pugliese, Luana Marano, Orsola Vitagliano, Luigia Luciano, Fiorella Alfinito, Fabrizio Pane, Antonio Maria Risitano
MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (MDS) WITH DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA): ROLE OF LENALIDOMIDE
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 61) **Claudio Cerchione**, Vincenzo Russo, Francesca Tucci, Giuseppe Loffredo, Giuseppe Menna, Rosanna Parasole, Fara Petruzzello, Nicoletta Marra, Francesco Menna, Nicoletta Crescenzo, Vincenzo Poggi
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS): EXPERIENCE OF OUR AIEOP DEPARTMENT
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 62) Giovanna Giagnuolo, **Claudio Cerchione**, Piera Angelillo, Simona Avilia, Orsola Vitagliano, Novella Pugliese, Luana Marano, Fiorella Alfinito, Fabrizio Pane, Giuseppe Cerciello
BENEFITS OF THE USE OF AZACITIDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 63) Fonti R, Pace L, **Cerchione C**, Catalano L, Seneca E, Madonna E, De Luca S, Pane F, Salvatore M, Del Vecchio S.
ROLE OF 18-FDG-PET/CT, 99MTC-MIBI AND MRI IN THE PREDICTION OF OUTCOME OF MULTIPLE MYELOMA
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 64) Barra G, **Cerchione C**, Madonna E, Pasquale G, Sementa A, Pane F, Catalano L, De Palma R.
OVEREXPRESSION OF SPHINGOSINE KINASE 2 IN MULTIPLE MYELOMA
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 65) Luana Marano, Novella Pugliese, **Claudio Cerchione**, Giuliana Beneduce, Concetta Quintarelli, Biagio De Angelis, Vincenzo Martinelli, Fabrizio Pane
MUCOCUTANEOUS TOXICITY INDUCED BY HYDROXYUREA IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

- 66) Novella Pugliese, Luana Marano, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Nicola Esposito, **Claudio Cerchione**, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
INTERFERON ALPHA IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA
Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013
- 67) Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Luana Marano, Santa Errichiello, Nicola Esposito, Maddalena Raia, **Claudio Cerchione**, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane
THE INTERFERON SCORE TOWARDS INTERFERON ALPHA TAILORED THERAPY IN ESSENTIAL THROMBOCYTHEMIA
ASH Abstract Book, December 2013
- 68) Claudio Cerchione, Mario Masarone, Marcello Persico, Giuliana Beneduce, Clementina Cimmino, Roberta Della Pepa, Serena Luponio, Ilaria Peluso, Novella Pugliese, Elisa Seneca, Marianna Notarangelo, Ciro Mainolfi, Marco Picardi, Fabrizio Pane, Amalia De Renzo
ROLE OF PROPHYLAXIS WITH LAMIVUDINE IN MAINTENANCE TREATMENT WITH RITUXIMAB IN NON HODGKIN LYMPHOMA CD20+
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 69) Emanuela Madonna, Luigia Simeone, Marta Raimondo, Claudio Cerchione, Amalia De Renzo, Federico Chiurazzi, Fabrizio Pane
SECONDARY MALIGNANCIES IN CHRONIC LYMPHOCYTIC LEUKEMIA: OUR EXPERIENCE
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 70) Claudio Cerchione, Emanuela Madonna, Anna Emanuele Pareto, Luana Marano, Novella Pugliese, Ilaria Peluso, Elisa Seneca, Giuseppe Cerciello, Simona Avilia, Santina Basile, Fabrizio Pane, Lucio Catalano
MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH BENDAMUSTINE
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 71) Amalia De Renzo, Roberta Della Pepa, Serena Luponio, Claudio Cerchione, Giuliana Beneduce, Ilaria Migliaccio, Novella Pugliese, Clementina Cimmino, Elisa Seneca, Anna Emanuele Pareto, Orsola Vitigliano, Luigia Simeone, Fabrizio Pane, Giuseppe Spadaro
RITUXIMAB-INDUCED HYPOGAMMAGLOBULINEMIA AND SUPPORTIVE INTRAVENOUS IG (IVIG) TREATMENT IN PATIENTS WITH NON HODGKIN LYMPHOMA
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 72) Amalia De Renzo, Claudio Cerchione, Fabiana Perna, Mario Masarone, Marcello Persico, Roberta Della Pepa, Clementina Cimmino, Serena Luponio, Ilaria Peluso, Novella Pugliese, Elisa Seneca, Ciro Mainolfi, Ilario De Sio, Giuseppe Ciana, Marco Picardi, Fabrizio Pane
MANAGEMENT OF PRIMARY HEPATIC NON-HODGKIN'S LYMPHOMA AND CORRELATION WITH HCV INFECTION: EXCELLENT RESULTS WITH CONVENTIONAL CHEMOTHERAPY
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 73) Novella Pugliese, Elisa Seneca, Lucio Catalano, Marco Picardi, Clementina Cimmino, Claudio Cerchione, Maria Di Perna, Fabrizio Pane, Amalia De Renzo
RISK OF SECOND MULTIPLE MYELOMA AFTER NON-HODGKIN AND HODGKIN LYMPHOMA
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 74) Claudio Cerchione, Clementina Cimmino, Novella Pugliese, Elisa Seneca, Roberta Della Pepa, Serena Luponio, Ciro Mainolfi, Fabrizio Pane, Amalia De Renzo
MANAGEMENT OF RELAPSED/REFRACTORY LYMPHOMA WITH BRENTUXIMAB VEDOTIN: OUR EXPERIENCE IN THE TREATMENT OF YOUNG PATIENTS
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 75) Claudio Cerchione, Santina Basile, Vincenzo Russo, Elisa Seneca, Fabrizio Pane, Lucio Catalano
PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 76) Claudio Cerchione, Serena Luponio, Roberta Della Pepa, Ilaria Migliaccio, Giuliana Beneduce, Novella Pugliese, Elisa Seneca, Ernesto Cimino, Antonio Coppola, Anna Maria Cerbone, Antonella Tufano, Marianna Notarangelo, Ilaria Peluso, Giovanni Di Minno, Fabrizio Pane, Amalia De Renzo

ACQUIRED HEMOPHILIA IN ELDERLY PATIENTS WITH NON HODGKIN'S LYMPHOMA

Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

- 77) Claudio Cerchione, Mario Masarone, Marcello Persico, Giuseppe Signoriello, Fabiana Perna, Clementina Cimmino, Novella Pugliese, Elisa Seneca, Ilaria Peluso, Marianna Notarangelo, Fabrizio Pane, Amalia De Renzo
PROPHYLAXIS WITH LAMIVUDINE FOR THE PREVENTION OF REACTIVATION IN OCCULT HEPATITIS B (OBI) IN NHL : A COST-EFFECTIVE ANALYSIS
Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014
- 78) Claudio Cerchione, Orsola Vitagliano, Anna Emanuele Pareto, Ilaria Soriente, Paolo Danise, Fiorella Alfinito, Fabrizio Pane
Analisi della risposta agli agenti eritrostimolanti in una coorte di pazienti affetti da syndrome mielodisplastica low-risk afferenti al Registro Campano per le MDS
Libro dei lavori - Italian Red Cell Club 2014 – San Marcellino e Festo - Napoli
- 79) Cerchione C, Basile S, Russo V, Seneca E, Pane F, Catalano L
MANAGEMENT OF POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: ROLE OF PEGFILGRASTIM
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 80) Alfinito F, Cerchione C, Vitagliano O, Pareto AE, Barca R, Cerciello G, Soriente I, D'Arco AM, Pane F, Danise P
MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 81) Pugliese N, Seneca E, Catalano L, Picardi M, Cimmino C, Luponio S, Cerchione C, Di Perna M, Pane F, De Renzo A
INCIDENCE OF MULTIPLE MYELOMA FOLLOWING THERAPY FOR NON-HODGKIN AND HODGKIN LYMPHOMA
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 82) Cerchione C, Masarone M, Persico M, Beneduce G, Cimmino C, Luponio S, Pugliese N, Seneca E, Notarangelo M, Mainolfi C, Picardi M, Pane F
PROPHYLAXIS WITH LAMIVUDINE IN MAINTENANCE TREATMENT WITH RITUXIMAB IN NON HODGKIN LYMPHOMA CD20+
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 83) Cerchione C, De Renzo A, Perna F, Masarone M, Persico M, Della Pepa R, Cimmino C, Luponio S, Pugliese N, Seneca E, Peluso I, Ciana G, Mainolfi C, De Sio I, Picardi M, Pane F
PRIMARY HEPATIC NON-HODGKIN'S LYMPHOMA AND CORRELATION WITH HCV INFECTION: EXCELLENT RESULTS WITH CONVENTIONAL CHEMOTHERAPY
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 84) Cerchione C, Madonna E, Pareto AE, Basile S, Peluso I, Vitagliano O, Cimmino C, Simeone L, Seneca E, Pugliese N, Marano L, Pane F, Catalano L
ROLE OF BENDAMUSTINE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 85) Cerchione C, Cimmino C, Luponio S, Della Pepa R, Migliaccio I, Beneduce G, Pugliese N, Seneca E, Cimmino E, Coppola A, Cerbone AM, Tufano A, Notarangelo M, Peluso I, Di Minno G, Pane F, De Renzo A
MANAGEMENT OF ACQUIRED HEMOPHILIA IN ELDERLY PATIENTS WITH NON HODGKIN'S LYMPHOMA
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 86) Cerchione C, Masarone M, Persico M, Perna F, Cimmino C, Peluso I, Notarangelo M, Pane F, De Renzo A
COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAMIVUDINE FOR THE PREVENTION OF REACTIVATION IN OCCULT HEPATITIS B (OBI) IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING CHEMOTHERAPY WITH AND WITHOUT RITUXIMAB
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 87) Cerchione C, Cimmino C, Pugliese N, Seneca E, Mainolfi C, Pane F, De Renzo A
BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY LYMPHOMA: OUR EXPERIENCE IN THE TREATMENT OF YOUNG PATIENTS
Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014
- 88) De Renzo A, Della Pepa R, Luponio S, Cerchione C, Beneduce G, Migliaccio I, Pugliese N, Cimmino C, Seneca E, Pareto

AE, Vitagliano O, Simeone L, Pane F, Spadaro G

SUPPORTIVE INTRAVENOUS IG (IVIG) TREATMENT IN RITUXIMAB-INDUCED HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH NON HODGKIN LYMPHOMA

Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

- 89) Cerchione C, Vitagliano O, Simeone L, Pareto AE, Soriente I, D'Arco AM, Danise P, Alfinito F, Pane F
MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE
Leuk Res Vol. 39 Suppl 1, S1-S166 (13th International Symposium on Myelodysplastic Syndromes (MDS))
- 90) Cerchione C, De Renzo A, Masarone M, Cimmino C, Raimondo M, Signoriello G, Notarangelo M, Giagnuolo G, Persico M, Pane F
COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAMIVUDINE FOR PREVENTION OF REACRIVATION IN OCCULT HEPATITIS B (OBI) IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING CHEMOTHERAPY
Haematologica Abstract Book, EHA Vienna, June 2015
- 91) Cerchione C, Vitagliano O, Simeone L, Pareto AE, Soriente I, D'Arco AM, Danise P, Alfinito F, Pane F
MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE
Haematologica Abstract Book, EHA Vienna, June 2015
- 92) Cerchione C, De Renzo A, Masarone M, Cimmino C, Persico M, Notarangelo M, Perna F, Mainolfi C, De Sio I, Ciana G, Picardi M, Pane F
MANAGEMENT OF PRIMARY HEPATIC NON HODGKIN'S LYMPHOMA AND CORRELATION WITH HCV INFECTION: EXCELLENT RESULTS WITH CONVENTIONAL CHEMOTHERAPY
Haematologica Abstract Book, EHA Vienna, June 2015
- 93) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F
BENDAMUSTINE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE
Haematologica Abstract Book, EHA Vienna, June 2015
- 94) **Cerchione C**, Catalano L, Pareto A.E., Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F
BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE
Leuk Res Vol 15, Suppl 3, September 2015
- 95) **Cerchione C**, Catalano L, Pareto A.E., Marano L, Basile S, Pane F
PEGYLATED DOXORUBICINE, CYCLOPHOSPHAMIDE AND DEXAMETASONE (CED): A NEW OPPORTUNITY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Leuk Res Vol 15, Suppl 3, September 2015
- 96) Cerchione C, De Renzo A, Cimmino C, Raimondo M, Marano L, Madonna E, Di Perna M, Russo V, Mainolfi C, Picardi M, Pane F
BRENTUXIMAB VEDOTIN IN THE MANAGEMENT OF RELAPSED/REFRACTORY LYMPHOMA IN YOUNG PATIENTS: OUR REAL-LIFE EXPERIENCE
Haematologica Abstract Book, Sie Firenze, October 2015
- 97) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F
BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE
Haematologica Abstract Book, Sie Firenze, October 2015
- 98) Cerchione C, Vitagliano O, Simeone L, Pareto AE, Cerciello G, Soriente I, D'Arco AM, Danise P, Alfinito F, Pane F
MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS (ESAs): EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE
Haematologica Abstract Book, Sie Firenze, October 2015

- 99) **Claudio Cerchione**, Catalano L, Pareto AE, Marano L, Basile S, Pane F
PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CED): A NEW OPPORTUNITY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Haematologica Abstract Book, Sie Firenze, October 2015
- 100) Cerchione C, De Renzo A, Masarone M, Cimmino C, Raimondo M, Signoriello G, Notarangelo M, Giagnuolo G, Di Perna M, Russo V, Persico M, Pane F
COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAMIVUDINE FOR PREVENTION OF REACTIVATION IN OCCULT HEPATITIS B IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING CHEMOTHERAPY
Haematologica Abstract Book, Sie Firenze, October 2015
- 101) Cerchione C, De Renzo A, Masarone M, Cimmino C, Persico M, Notarangelo M, Perna F, Mainolfi C, De Sio I, Cincia G, Picardi M, Pane F
MANAGEMENT OF PRIMARY HEPATIC NON-HODGKIN'S LYMPHOMA (PHL)
Haematologica Abstract Book, Sie Firenze, October 2015
- 102) Cerchione C, De Renzo A, Cimmino C, Raimondo M, Di Perna M, Russo V, Picardi M, Pane F
PEGFILGRASTIM IN PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING RITUXIMAB-BENDAMUSTINE TREATMENT IN INDOLENT NON HODGKIN LYMPHOMA: A REAL-LIFE EXPERIENCE
Haematologica Abstract Book, Sie Firenze, October 2015
- 103) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F
"Bendamustine-Bortezomib-Desametasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A real-life experience"
Blood December 3, 2015, 126 (23)
- 104) Cerchione C, De Renzo A, Masarone M, Cimmino C, Di Perna M, Signoriello G, Persico M, Pane F
Lamivudine for prevention of reactivation in occult hepatitis B in patients with non-Hodgkin Lymphoma CD20+ undergoing chemotherapy: a cost-effective analysis
Haematologica Abstract Book, EHA Copenhagen, June 2016
- 105) Cerchione C, Vitagliano O, Pareto AE, Di Perna M, Cerciello G, Soriente I, Alfinito F, Pane F
Management of myelodysplastic syndromes with Erythropoiesis stimulating agents (ESAs): a real-life experience
Haematologica Abstract Book, EHA Copenhagen, June 2016
- 106) Cerchione C, De Renzo A, Masarone M, Cimmino C, Della Pepa R, Di Perna M, Mainolfi C, De Sio I, Cincia G, Persico M, Pane F
Management of primary hepatic non-Hodgkin's lymphoma (PHL)
Haematologica Abstract Book, EHA Copenhagen, June 2016
- 107) Gravetti A, Cerchione C, Casoria A, Pugliese N, Marano L, De Gregorio F, Di Perna M, Picardi M, Martinelli V, Pane F
Use of combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy
Haematologica Abstract Book, EHA Copenhagen, June 2016
- 108) De Nisco M, Cerchione C, Martinelli V, Pugliese N, Pedatella S, Catalano L, Manfra M, Marra N, Iula VD, Pagano F, Picardi M, Pane F
An HPLC and 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance
Haematologica Abstract Book, EHA Copenhagen, June 2016
- 109) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Ferrara F, Pane F
Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience
Haematologica Abstract Book, EHA Copenhagen, June 2016
- 110) Cerchione C, De Renzo A, Cimmino C, Raimondo M, Di Perna M, Picardi M, Pane F
Pegfilgrastim in primary prophylaxis of febrile neutropenia during rituximab-bendamustine treatment in indolent non Hodgkin lymphoma: a real-life experience
Haematologica Abstract Book, EHA Copenhagen, June 2016

- 111) Cerchione C, Nappi D, Salvatore D, Migliaccio I, Pane F, Catalano L
Pegfilgrastim versus filgrastim in the management of post-chemotherapy neutropenia in relapsed and refractory multiple myeloma in treatment with BVD (bendamustine-bortezomib-dexamethasone)
 Haematologica Abstract Book, EHA Copenhagen, June 2016
- 112) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Caprioli V, Frieri C, Pane F, Picardi M
Front-line central vascular access devices in acute leukemias – peripherally inserted central catheter (PICC) versus traditional central venous catheter (CVC): a phase IV randomized trial (NCT02405728)
 Haematologica Abstract Book, EHA Copenhagen, June 2016
- 113) Cerchione C, Di Perna M, Pugliese N, Della Pepa R, Raimondo M, Pane F, Picardi M
Bendamustine-brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma
 Haematologica Abstract Book, EHA Copenhagen, June 2016
- 114) Cerchione C, Catalano L, Pareto AE, Basile S, Peluso I, Marano L, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F
Role of Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience
 SIICA: Multiple Myeloma 2016 – Perspectives for a paradigm change – Catanzaro – June 2016
- 115) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M
Front-line central vascular access devices in acute leukemias – peripherally inserted central catheter (PICC) versus traditional central venous catheter (CVC): a phase IV randomized trial (NCT02405728)
 ASH meeting on hematologic malignancies, Chicago, September 2016
- 116) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Raimondo M, Pane F, Picardi M
Bendamustine-brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma
 ASH meeting on hematologic malignancies, Chicago, September 2016
- 117) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F
Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience
 ESH 3rd International Conference on Multiple Myeloma – Milan – October 2016 (Oral presentation)
- 118) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Raimondo M, Pane F, Picardi M
Bendamustine-brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma
 Haematologica Abstract Book, SIES Rimini, October 2016
- 119) Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D'Arco AM, Danise P, Alfinito F, Pane F
Management of myelodysplastic syndromes with Erythropoiesis stimulating agents (ESAs) : evaluation of erythropoietic aspects and analysis of response
 Haematologica Abstract Book, SIES Rimini, October 2016
- 120) Cerchione C, Luciano L, Cimmino C, Memoli M, Pane F
Imatinib mesylate and cardiac function
 Haematologica Abstract Book, SIES Rimini, October 2016
- 121) Cerchione C, De Renzo A, Masarone M, Cimmino C, Persico M, Notarangelo M, Rosato V, Della Pepa R, Pugliese N, Mainolfi C, De Sio I, Pane F, Picardi M
Primary hepatic non Hodgkin lymphoma: high prevalence of hepatitis C virus infection and efficacy of the conventional six courses of anthracycline-based chemotherapy
 Haematologica Abstract Book, SIES Rimini, October 2016
- 122) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Caprioli V, Frieri C, Pane F, Picardi M
Front-line central vascular access devices in acute leukemias – peripherally inserted central catheter (PICC) versus traditional central venous catheter (CVC): a phase IV randomized trial (NCT02405728)
 Haematologica Abstract Book, SIES Rimini, October 2016

- 123) Cerchione C, Gravetti A, Casoria A, Pugliese N, Marano L, Raimondo M, Picardi M, Martinelli V, Pane F
Use of combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy
 Haematologica Abstract Book, SIES Rimini, October 2016
- 124) De Nisco M, Cerchione C, Martinelli V, Pugliese N, Pedatella S, Catalano L, Manfra M, Marra N, Iula VD, Pagano F, Picardi M, Bolognese A, Pane F
An HPLC and ¹H NMR Study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance
 Haematologica Abstract Book, SIES Rimini, October 2016
- 125) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F
Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A real-life experience
 Haematologica Abstract Book, SIES Rimini, October 2016
- 126) Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, Migliaccio I, Picardi M, Pane F
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with Bendamustine-Bortezomib-Dexamethasone
 Haematologica Abstract Book, SIES Rimini, October 2016
- 127) Cerchione C, Di Perna M, Nappi D, Zacheo I, Pane F, Catalano L
Lenalidomide twenty-five mg every other day in patients affected by multiple myeloma and renal failure
 Haematologica Abstract Book, SIES Rimini, October 2016
- 128) Pugliese N, Di Perna M, Cozzolino I, Ciancia G, Pettinato G, Varone V, Zeppa P, Masone S, Cerchione C, Della Pepa R, Salvatore C, Pane F, Picardi M
Randomized Comparison of Power Doppler Ultrasonography-Guided-Core-Needle Biopsy with Open Surgical Biopsy for the Characterization of Lymphadenopathies in patients with suspected lymphoma
 Blood 2016 128: 685 (ASH 2016 Abstract Book)
- 129) Cerchione C, Di Perna M, Nappi D, Zacheo I, Pane F, Catalano L
Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience
 16TH International Myeloma Workshop 2017, New Delhi, India
- 130) Cerchione C, Di Perna M, Nappi D, Zacheo I, Pane F, Catalano L
Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience
 16TH International Myeloma Workshop 2017, New Delhi, India
- 131) Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D'Arco AM, Danise P, Alfinito F, Pane F
Management of myelodysplastic syndromes with erythropoiesis stimulating agents (ESAs) in real-life experience: an update from RECAMDS
 Leuk Res Abstract Book, 14TH International Symposium on Myelodysplastic Syndromes (MDS 2017), Valencia, May 2017
- 132) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M
High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma
 14TH International Conference on Malignant Lymphoma, Lugano, June 2017
- 133) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M
Front-line vascular access devices in acute leukemias – peripherally inserted central catheter (PICC) versus traditional center venous catheter (CVC): a phase IV randomized trial (NCT02405728)
 Oral communication - Haematologica Abstract Book, EHA Madrid, June 2017
- 134) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Marano L, Peluso I, Simeone L, Vitalgiano O, Palmieri S, Rocco S, Ferrara F, Pane F
Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience
 Haematologica Abstract Book, EHA Madrid, June 2017

- 135) Della Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, Cerchione C, Pane F
Nodular lymphocyte predominant Hodgkin lymphoma: a new risk adapted treatment strategy based on Rituximab
 Haematologica Abstract Book, EHA Madrid, June 2017
- 136) Cerchione C, Catalano L, Pareto AE, Nappi D, Peluso I, Ferrara K, Di Perna M, Zacheo I, Pane F
Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience
 Haematologica Abstract Book, EHA Madrid, June 2017
- 137) Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Catalano L, Nappi D, Cincia G, Pettinato G, Pane F, Martinelli V
Use of combined oral fentanyl citrate (Actiq) and midazolam as premedication for bone marrow biopsy in patients with hematological malignancies: a randomized controlled patient blinded clinical trial
 Haematologica Abstract Book, EHA Madrid, June 2017
- 138) Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D'Arco AM, Danise P, Alfinito F, Pane F
Management of myelodysplastic syndromes with erythropoiesis stimulating agents (ESAs) in real-life experience: an update from RECAMDS
 Haematologica Abstract Book, EHA Madrid, June 2017
- 139) Pugliese N, Simeone L, Della Pepa R, Giordano C, Cappuccio I, Zacheo I, Campagna G, Cerchione C, Zeppa P, Salvatore C, Pane F, Picardi M
Impact on survival of early detection of recurrence in the follow-up of high risk Hodgkin lymphoma in first complete remission
 Haematologica Abstract Book, EHA Madrid, June 2017
- 140) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M
High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma
 Haematologica Abstract Book, EHA Madrid, June 2017
- 141) Cerchione C, Ferrara K, Peluso I, Nappi D, Di Perna M, Zacheo I, Pareto AE, Pane F, Catalano L
Carfilzomib-lenalidomide-dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience
 Haematologica Abstract Book, EHA Madrid, June 2017
- 142) Cerchione C, Catalano L, Pareto AE, Nappi D, Peluso I, Ferrara K, Di Perna M, Zacheo I, Romano A, Pane F
Full standard doses of lenalidomide in bortezomib-refractory Multiple Myeloma patients affected by renal failure: a real-life experience
 Clinical Myeloma & Lymphoma, Vol. 17, Suppl. 2, September 2017
- 143) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Romano A, Ferrara F, Pane F
Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience
 Clinical Myeloma & Lymphoma, Vol. 17, Suppl. 2, September 2017
- 144) Cerchione C, Ferrara K, Peluso I, Nappi D, Di Perna M, Zacheo I, Pareto AE, Pane F, Catalano L
Front-line vascular access devices in acute leukemias – Peripherally Inserted Central Catheter (PICC) versus traditional Central Venous Catheter (CVC): A Phase IV Randomized Trial (NCT02405728)
 Clinical Myeloma & Lymphoma, Vol. 17, Suppl. 2, September 2017
- 145) Cerchione C, Picardi M, Di Perna M, Della Pepa R, Pugliese N, Pane F
Front-line vascular access devices in acute leukemias – peripherally inserted central catheter (PICC) versus traditional center venous catheter (CVC): a phase IV randomized trial (NCT02405728)
 Oral communication - Haematologica Abstract Book, SIE Roma, October 2017
- 146) Palmieri S, Rocco S, Migliaccio I, Cerchione C, Catalano L, Ferrara K, Peluso I, Monaco G, Farina G, Gagliardi A, Barone M, Esposito D, Amico V, Arcamone M, Fontana R, Sica A, Pane F, Ferrara F
KRD (Carfilzomib plus Lenalidomide plus Dexamethasone) in relapsed or refractory Multiple Myeloma in Campania Region: a one-year survey

- 147) Cerchione C, Picardi M, Pugliese N, Della Pepa R, Cappuccio I, Campagna G, Fanelli F, Gravetti A, Casoria A, Catalano L, Nappi D, Ciancia G, Pettinato G, Pane F, Martinelli V
Use of combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy
Haematologica Abstract Book, SIE Roma, October 2017
- 148) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Romano A, Ferrara F, Pane F
Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience
Haematologica Abstract Book, SIE Roma, October 2017
- 149) Della Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, Cerchione C, Pane F
Nodular lymphocyte predominant Hodgkin lymphoma: a new risk adapted treatment strategy based on Rituximab
Haematologica Abstract Book, SIE Roma, October 2017
- 150) Cerchione C, Picardi M, Di Perna M, Della Pepa R, Pugliese N, Della Pepa R, Pane F
High-dose bendamustine plus brentuximab vedotin is effective and has a favourable toxicity profile in the treatment of refractory or relapsed Hodgkin lymphoma
Haematologica Abstract Book, SIE Roma, October 2017
- 151) Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Pane F, Catalano L
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma: a real-life experience
Haematologica Abstract Book, SIE Roma, October 2017
- 152) Cerchione C, Catalano L, Pareto AE, Nappi D, Peluso I, Ferrara K, Di Perna M, Zacheo I, Pane F
Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience
Haematologica Abstract Book, SIE Roma, October 2017
- 153) Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D'Arco AM, Danise P, Alfinito F, Pane F
Management of low-risk myelodysplastic syndromes with erythropoiesis stimulating agents (ESAs) in real-life experience: an update from RECAMDS (Registro Campano delle sindromi mielodisplastiche)
Haematologica Abstract Book, SIE Roma, October 2017
- 154) Pugliese N, Simeone L, Della Pepa R, Giordano C, Cappuccio I, Zacheo I, Campagna G, Cerchione C, Zeppa P, Salvatore C, Pane F, Picardi M
Impact on survival of early detection of recurrence in the follow-up of high risk Hodgkin lymphoma in first complete remission
Haematologica Abstract Book, SIE Roma, October 2017
- 155) Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
Haematologica Abstract Book, SIE Roma, October 2017
- 156) Cerchione C, Ferrara K, Peluso I, Nappi D, Di Perna M, Zacheo I, Pareto AE, Pane F, Catalano L
Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience
Haematologica Abstract Book, SIE Roma, October 2017
- 157) Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Ciancia G, Pane F, Martinelli V
Combined oral fentanyl citrate (Actiq) and midazolam as premedication for bone marrow aspiration and biopsy in patients with hematological malignancies: a randomized, controlled clinical trial
VII Corso di Alta Formazione in terapia del dolore, Abstract Book, Capri (NA); October 2017
- 158) Cerchione C, Nappi D, Pareto AE, Romano A, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L
Safety and comfort of domestic bortezomib injection in real-life experience
Blood December 2017 (ASH 2017 Abstract Book)

- 159) Cerchione C, Di Perna M, Pugliese N, Della Pepa R, Pane M, Picardi M
High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma
 Blood December 2017 (ASH 2017 Abstract Book)
- 160) Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Ciancia G, Pane F, Martinelli V
Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy
 Blood December 2017 (ASH 2017 Abstract Book)
- 161) Palmieri S, Rocco S, Migliaccio I, Cerchione C, Catalano L, Ferrara K, Peluso I, Monaco G, Farina G, Gagliardi A, Barone M, Esposito D, Amico V, Arcamone M, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F
KRD (Carfilzomib plus lenalidomide plus dexamethasone) in relapsed or refractory multiple myeloma: a real life survey in Campania region in southern Italy
 Haematologica Abstract Book, EMN Turin, April 2018, s1
- 162) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Romano A, Palmieri S, Rocco S, Monaco G, Romano A, Pane F, Ferrara F
Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma
 Haematologica Abstract Book, EMN Turin, April 2018, s1
- 163) Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Pane F, Catalano L
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
 Haematologica Abstract Book, EMN Turin, April 2018, s1
- 164) Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Pane F, Catalano L.
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
 Haematologica Abstract Book, EMN Turin, April 2018, s1
- 165) Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L
Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience
 Haematologica Abstract Book, EMN Turin, April 2018, s1
- 166) Cerchione C, Nappi D, Pareto AE, Romano A, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L
Safety and comfort of domestic bortezomib injection in real-life experience
 Haematologica Abstract Book, EMN Turin, April 2018, s1
- 167) Pugliese N, Giordano C, Nappi D, Luciano L, Cerchione C, Annunziata M, Casale B, Crisà E, Villa MR, Pezzullo L, Iovine M, Picardi M, Simeone L, Pane F, Martinelli V
Ruxolitinib and hydroxyurea combination for the treatment of myelofibrosis
 HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)
- 168) Raimondo M, Della Pepa R, Giordano C, Pugliese N, Cerchione C, Trastulli F, Mortaruolo C, Zacheo I, Picardi M, Pane F
Efficacy and safety of high dose bendamustine plus brentuximab vedotin in refractory or relapsed classical Hodgkin lymphoma: a single center experience
 HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)
- 169) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Monaco G, Romano A, Pane F, Ferrara F
Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma
 HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)
- 170) Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Romano A, Pane F, Catalano L
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
 HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)
- 171) Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L
Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience
 HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

- 172) Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)
- 173) Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Cincia G, Pettinato G, Pane F, Martinelli V
Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy
HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)
- 174) Cerchione C, Catalano L, Nappi D, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Romano A, Ferrara F, Pane F
Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma
Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018
- 175) Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Pane F, Catalano L
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018
- 176) Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018
- 177) Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.
Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone
Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018
- 178) Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Cincia G, Pane F, Martinelli V
Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy
Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018
- 179) Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Romano A, Pane F, Catalano L
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
ESH 4rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018
- 180) Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
ESH 4rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018
- 181) Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.
Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone
ESH 4rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018
- 182) Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L
Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience
ESH 4rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018
- 183) Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Romano A, Pane F, Catalano L
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
Hematology Abstract Book, SIES, October 2018 (Suppl. 2)
- 184) Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
Hematology Abstract Book, SIES, October 2018 (Suppl. 2)
- 185) Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Cincia G, Pane F, Martinelli V
Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

- 186) Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.
Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone
Hematology Abstract Book, SIES, October 2018 (Suppl. 2)
- 187) Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Monaco G, Romano A, Pane F, Ferrara F
Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma
Hematology Abstract Book, SIES, October 2018 (Suppl. 2)
- 188) Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L
Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience
Hematology Abstract Book, SIES, October 2018 (Suppl. 2)
- 189) Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
Blood December 2018 (ASH 2018 Abstract Book)
- 190) Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.
Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone
Blood December 2018 (ASH 2018 Abstract Book)
- 191) Samantha Bruno, Martina Pazzaglia, Claudio Cerchione, Simona Soverini, Michele Cavo, Lorenzo Montanaro, Giorgia Simonetti, Giovanni Martinelli. **Deep hypoxia and the genomic background cooperate to shape the metabolic profile of acute myeloid leukemia cells.** AACR 2019 Proceedings.
- 192) Giovanni Martinelli, Stefania Paolini, Claudio Cerchione, Alessandra Santoro, Valentina Robustelli, Simona Soverini, Caterina De Benedittis, Enrica Imbrogno, Andrea Ghelli Luserna Di Rora, Sarah Parisi, Chiara Sartor, Giovanni Marconi, Silvia Lo Monaco, Maria Chiara Abbenante, Maria Chiara Fontana, Antonella Padella, Anna Ferrari, Giorgia Simonetti, Elena Tenti, Federica Frabetti, Francesca Volpato, Samantha Bruno, Fabiana Mammoli, Maria Teresa Bocchicchio, Carmen Baldazzi, Cristina Papayannidis. **Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience.** AACR 2019 Proceedings.
- 193) Giorgia Simonetti, Antonella Padella, Eugenio Fonzi, Martina Pazzaglia, Margherita Perricone, Maria Chiara Fontana, Samantha Bruno, Maria Teresa Bocchicchio, Eugenia Franchini, Jacopo Nanni, Giovanni Marconi, Italo F. do Valle, Rossella De Tommaso, Anna Ferrari, Enrica Imbrogno, Claudio Cerchione, Cristina Papayannidis, Emanuela Ottaviani, Daniel Remondini, Giovanni Martinelli. **Metabolic profiling defines a new characterization of acute myeloid leukemia and identifies NPM1-mutated cases as a distinct subgroup.** AACR 2019 Proceedings.
- 194) C. Cerchione. **BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA.** Comy 2019 (Paris).
- 195) C. Cerchione. **CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA.** Comy 2019 (Paris).
- 196) C. Cerchione. **POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA.** Comy 2019 (Paris).
- 197) **PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE.** C. Cerchione. Comy 2019 (Paris).
- 198) Claudio Cerchione, Giovanni Martinelli, Davide Nappi, Anna Emanuele Pareto, Maria Di Perna, Katia Ferrara, Fabrizio Pane, Lucio Catalano, **Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma.** ASCO 2019 Chicago. J Clin Oncol 37, 2019 (suppl; abstr e19522)
- 199) Claudio Cerchione, Giovanni Martinelli, Lucio Catalano, Novella Pugliese, Roberta Della Pepa, Angela Gravetti, Davide Nappi, Fabrizio Pane, Vincenzo Martinelli; **Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy.** ASCO 2019 Chicago. J Clin Oncol 37, 2019 (suppl; abstr e18313)

- 200) Giovanni Martinelli, Stefania Paolini, Claudio Cerchione, Alessandra Santoro, Valentina Robustelli, Simona Soverini, Caterina De Benedittis, Enrica Imbrogno, Andrea Ghelli Luserna di Rorà, Sarah Parisi, Chiara Sartor, Giovanni Marconi, Silvia Lo Monaco, Maria Chiara Abbenante, Maria Chiara Fontana, Antonella Padella, Anna Ferrari, Giorgia Simonetti, Cristina Papayannidis. **Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience.** ASCO 2019 Chicago. J Clin Oncol 37, 2019 (suppl; abstr e18522).
- 201) C. Cerchione, V. Guadagnuolo, C. Papayannidis, I. Iacobucci, A. Padella, G. Simonetti, S. Paolini, M. Abbenante, S. Parisi, F. Volpato, M. C. Fontana, E. Ottaviani, N. Testoni, C. Baldazzi, M. Delledonne, C. Fili, M. Malagola, F. Cattina, S. Bernardi, D. Russo, G. Martinelli. **A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 202) G. Simonetti, A. Padella, C. Mengucci, E. Fonzi, G. Picone, M. Pazzaglia, M. Perricone, M. Fontana, S. Bruno, M. T. Bochicchio, E. Franchini, J. Nanni, G. Marconi, I. F. do Valle, R. De Tommaso, A. Ferrari, M. Ghetti, R. Napolitano, C. Papayannidis, A. Ghelli Luseran di Rorà, C. Cerchione, E. Ottaviani, G. Castellani, D. Remondini, F. Capozzi, G. Martinelli. **A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 203) C. Cerchione, G. Martinelli, S. Rocco, S. Palmieri, D. Nappi, A. E. Pareto, F. Pane, L. Catalano, F. Ferrara, **BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/ NEW ARM IN NOVEL AGENTS' WORLD.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 204) C. Cerchione, G. Martinelli, D. Nappi, A. E. Pareto, M. Di Perna, K. Ferrara, A. Ferrari, G. Simonetti, F. Pane, L. Catalano. **CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 205) C. Cerchione, G. Martinelli, L. Catalano, N. Pugliese, R. Della Pepa, A. Gravetti, D. Nappi, F. Pane, V. Martinelli. **COMBINED ORAL ANALGESIA AND ANXIOLYSIS FOR PAIN ASSOCIATED WITH BONE MARROW ASPIRATION AND BIOPSY.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 206) C. Cerchione, G. Martinelli, I. Soriente, A. M. D'Arco, P. Danise, G. Cerciello, F. Pane, F. Alfinito. **ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES: RECAMDS TRIAL.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 207) C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, F. Pane, L. Catalano. **PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF THERAPY-RELATED NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 208) C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, M. Di Perna, K. Ferrara, A. Ferrari, G. Simonetti, F. Pane, L. Catalano. **POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 209) C. Cerchione, V. Guadagnuolo, C. Papayannidis, M.C. Fontana, A. Padella, I. Iacobucci, G. Simonetti, G. Marconi, S. Paolini, M. Abbenante, S. Parisi, F. Volpato, E. Ottaviani, M. Delledonne, G. Biasco, G. Martinelli, **SNP ARRAY REVEALS A NEW DELETION OF JAK2 IN AML PATIENTS.** HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
- 210) G. Simonetti, A. Padella, C. Mengucci, E. Fonzi, G. Picone, M. Pazzaglia, M. Perricone, M.C. Fontana, S. Bruno, M.T. Bochicchio, E. Franchini, J. Nanni, G. Marconi, I.F. do Valle, R. De Tommaso, A. Ferrari, M. Ghetti, R. Napolitano, C. Papayannidis, C. Cerchione, E. Ottaviani, G. Castellani, D. Remondini, F. Capozzi, G. Martinelli. **INTRACELLULAR AND SYSTEMIC METABOLIC PROFILING OF ACUTE MYELOID LEUKEMIA IMPROVES GENOMIC CLASSIFICATION AND SUGGESTS NOVEL THERAPEUTIC TARGETS.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 211) C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, M. Di Perna, K. Ferrara, G. Musuraca, A. Lucchesi, A. Ferrari, G. Simonetti, F. Pane, L. Catalano. **CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 212) A. Ferrari, S. Vitali, C. Baldazzi, G. Ferrari, V. Robustelli, A. Ghelli, E. Fonzi, M. Tebaldi, S. Salvi, C. Papayannidis, S. Paolini, A. Padella, M.T. Bochicchio, G. Pasquini, G. Simonetti, G. Musuraca, D. Cangini, B.M. Giannini, C. Cerchione, A. Santoro, J.M. Hernández-Rivas, D. Calistri, N. Testoni, D. Remondini, G. Martinelli. **ADULT TRIPLE NEGATIVE ACUTE**

LYMPHOBLASTIC LEUKEMIA FUSION DETECTION: THE CHALLENGE FOR ALTERNATIVE THERAPIES.

Hematologica Abstract Book October 2019 (SIE) Suppl.2

- 213) A. Ferrari, S. Vitali, V. Robustelli, A. Ghelli, C. Baldazzi, S. Righi, E. Fonzi, S. De Matteis, M. Ghetti, R. Napolitano, M. Tebaldi, S. Salvi, C. Papayannidis, G. Marconi, S. Paolini, G. Ferrari, M.C. Fontana, E. Imbrogno, A. Padella, G. Simonetti, G. Pasquini, D. Cangini, B.M. Giannini, **C. Cerchione**, A. Santoro, J.M. Hernández-Rivas, D. Calistri, G. Castellani, E. Sabattini, N. Testoni, D. Remondini, G. Martinelli. **HOW TO DETECT “3C-UP”, A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 214) **C. Cerchione**, G. Martinelli, L. Catalano, N. Pugliese, A. Gravetti, D. Nappi, S. Ronconi, D. Cangini, M.B. Giannini, M. Altini, F. Pane, V. Martinelli. **ROLE OF SEDOANALGESIA FOR PAIN ASSOCIATED WITH BONE MARROW ASPIRATION AND BONE BIOPSY.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 215) **C. Cerchione**, G. Martinelli, D. Nappi, A.E. Pareto, M. Di Perna, K. Ferrara, S. Ronconi, D. Cangini, V. Di Battista, M. Ceccolini, M. Altini, F. Pane, L. Catalano. **POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 216) **C. Cerchione**, L. Catalano, S. Rocco, S. Palmieri, D. Nappi, A.E. Pareto, S. Ronconi, M. Ceccolini, G. Martinelli, F. Pane, F. Ferrara, **BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 217) M.B. Giannini, D. Cangini, **C. Cerchione**, V. Di Battista, A. Lucchesi, G. Musuraca, M. Ceccolini, R. Sonia, G. Martinelli. **A RARE CASE OF HAIRY CELL LEUKEMIA IN ASSOCIATION WITH MAST-CELL LEUKEMIA.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 218) **C. Cerchione**, G. Martinelli, I. Soriente, A.M. D'Arco, P. Danise, G. Cerciello, V. Di Battista, D. Cangini, M.B. Giannini, F. Pane, F. Alfinito. **ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 219) **C. Cerchione**, G. Martinelli, D. Nappi, A.E. Pareto, A. Lucchesi, G. Musuraca, S. Ronconi, F. Pane, L. Catalano. **PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 220) M. Gentile, G. Specchia, D. Derudas, M. Galli, S. Rocco, C. Conticello, C. Califano, N. Giuliani, S. Mangiacavalli, E. Attingenti, A. Lombardo, M. Brunori, E. Rossi, E. Antonioli, R. Ria, R. Zambello, N. Di Renzo, G. Mele, G. Marcacci, P. Musto, S. Capalbo, N. Cascavilla, **C. Cerchione**, A. Belotti, C. Criscuolo, G. Uccello, P. Curci, E. Vigna, D. Vincelli, A. Bonalumi, A. Siniscalchi, R. Stocchi, M. Martino, S. Ballanti, D. Gangemi, A. Gagliardi, B. Gamberi, A. Pompa, A.G. Recchia, G. Tripepi, F. Frigeri, U. Consoli, S. Bringhen, E. Zamagni, F. Patriarca, V. De Stefano, F. Di Raimondo, F. Ferrara, F. Morabito, M.T. Petrucci, M. Offidani. **ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE (ELORD) AS SALVAGE THERAPY FOR PATIENTS WITH MULTIPLE MYELOMA: ITALIAN, MULTICENTER, RETROSPECTIVE CLINICAL EXPERIENCE WITH 300 CASES OUTSIDE OF CONTROLLED CLINICAL TRIALS.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 221) D. Cangini, **C. Cerchione**, M. B. Giannini, V. Di Battista, F. Frabetti, E. Petracci, S. Ronconi, G. Martinelli. **HIGH-DOSE MELPHALAN IS A SAFE CONDITIONING REGIMEN IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA.** Hematologica Abstract Book October 2019 (SIE) Suppl.2
- 222) **C. Cerchione**, L. Catalano, G. Martinelli, S. Rocco, S. Palmieri, D. Nappi, A.E. Pareto, S. Ronconi, F. Pane, F. Ferrara, **OLD/NEW IN NOVEL AGENTS' ERA: BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA.** Leukemia & Myeloma 2019 (October 23-26, 2019, New York) – American Journal of Hematology Abstract book
- 223) **C. Cerchione**, O. Vitagliano, A.E. Pareto, D. Nappi, P. Danise, I. Soriente, G. Cerciello, F. Pane, F. Alfinito, **Erythropoiesis stimulating agents (ESAs) in management of myelodysplastic syndromes: RECAMDS Trial.** EHA-SWG Scientific Meeting on Red Cells, 7-9 November 2019, Madrid, Spain
- 224) Patrizia Mondello, MD PhD MSc , Irene Dogliotti, MD , Jan-Paul Bohn , Federica Cavallo , Simone Ferrero, MD , Barbara Botto , **Claudio Cerchione, MD PhD** , Davide Nappi , Sonya De Lorenzo , Giovanni Martinelli, MD , Dominik Wolf, Univ. Prof. Dr. , Giacomo Loseto, MD , Salvatore Cuzzocrea, MD PhD , Wolfgang Willenbacher, MD PhD , Michael Mian, MD.

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. Blood (2019) 134 (Supplement_1 - ASH 2019 Abstract Book): 1565.

- 225) Elisa Brilli, PhD, Michela Asperti, PhD, Annalisa Castagna, B.S., PhD, **Claudio Cerchione, MD PhD**, Domenico Girelli, MD, PhD, Maura Poli, PhD, Germano Tarantino. **Effect of Oral Iron Treatment in Tmprss6 Knock-out Mouse Model** Blood (2019) 134 (Supplement_1 – ASH 2019 Abstract book): 2235.
- 226) **Claudio Cerchione**, Lucio Catalano, Davide Nappi, Stefano Rocco, Salvatore Palmieri, Anna Emanuele Pareto, Gerardo Musuraca, Fabrizio Pane, Felicetto Ferrara, Giovanni Martinelli **Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: Old/new in novel agents' era.** DOI: 10.1177/0300891620953388
- 227) **Claudio Cerchione**, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli **Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: Old/new in novel agents' era.** DOI: 10.1200/JCO.2020.38.15_suppl.e20517 Journal of Clinical Oncology 38, no. 15_suppl
- 228) Davide Nappi, Lucio Catalano, Anna Emanuele Pareto, Gerardo Musuraca, Fabrizio Pane, Giovanni Martinelli, **Claudio Cerchione**, **Carfilzomib-Lenalidomide-Dexamethasone in the management of Lenalidomide-refractory Multiple Myeloma.** DOI: 10.1200/JCO.2020.38.15_suppl.e20517 Journal of Clinical Oncology 38, no. 15_suppl
- 229) **Claudio Cerchione**, Giovanni Martinelli, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, Alessandro Lucchesi, Fabrizio Pane, Lucio Catalano. **Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone.** DOI: 10.1200/JCO.2020.38.15_suppl.e20514 Journal of Clinical Oncology 38, no. 15_suppl
- 230) G. Marconi, A. Piciocchi, S. Capria, E. Audisio, E. Borlenghi, G. Priolo, M. Breccia, I. Urbino, G. Rossi, G. Simonetti, C. Papayannidis, E. Crea, C. Cerchione, R. M. Lemoli, F. Ciceri, V. Gaidano, A. Cignetti, P. Fazi, M. Vignetti, G. Martinelli **SAFETY RUN-IN COHORT 1 OF GIMEMA AML1718: A SAFETY RUN-IN AND PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, CYRATABINE AND IDARUBICINE (V-FLAI) IN INDUCTION THERAPY OF ACUTE MYELOID LEUKEMIA** HemaSphere, 2020;4:S1, Abstract Book, DOI: <http://dx.doi.org/10.1097/HS9.0000000000000404>
- 231) **C. Cerchione**, F. Alfinito, O. Vitagliano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, I. Soriente, C. Lilli, P. Danise, F. Pane, G. Martinelli **ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELOYDYSPLASTIC SYNDROMES** HemaSphere, 2020;4:S1, Abstract Book, DOI: <http://dx.doi.org/10.1097/HS9.0000000000000404>
- 232) **C. Cerchione**, L. Catalano, D. Nappi, A. E. Pareto, G. Musuraca, S. Ronconi, M. Ceccolini, A. Lucchesi, F. Pane, G. Martinelli **CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA** HemaSphere, 2020;4:S1, Abstract Book, DOI: <http://dx.doi.org/10.1097/HS9.0000000000000404>
- 233) **C. Cerchione**, L. Catalano, S. Rocco, S. Palmieri, D. Nappi, A. E. Pareto, S. Ronconi, G. Musuraca, A. Lucchesi, M. Ceccolini, F. Pane, F. Ferrara, G. Martinelli **BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA** HemaSphere, 2020;4:S1, Abstract Book, DOI: <http://dx.doi.org/10.1097/HS9.0000000000000404>
- 234) C. Cerchione, L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Frabetti, F. Pane, G. Martinelli **POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA** HemaSphere, 2020;4:S1, Abstract Book, DOI: <http://dx.doi.org/10.1097/HS9.0000000000000404>
- 235) C. Cerchione L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Mammoli, F. Pane, G. Martinelli **PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDEDEXAMETHASONE** HemaSphere, 2020;4:S1, Abstract Book, DOI: <http://dx.doi.org/10.1097/HS9.0000000000000404>
- 236) **C. Cerchione**, F. Alfinito, O. Vitagliano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, I. Soriente, C. Lilli, P. Danise, F. Pane, G. Martinelli

ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELOYDYSPLASTIC SYNDROMES

Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020

- 237) **C. Cerchione**, L. Catalano, D. Nappi, A. E. Pareto, G. Musuraca, S. Ronconi, M. Ceccolini, A. Lucchesi, F. Pane, G. Martinelli
CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020
- 238) **C. Cerchione**, L. Catalano, S. Rocco, S. Palmieri, D. Nappi, A. E. Pareto, S. Ronconi, G. Musuraca, A. Lucchesi, M. Ceccolini, F. Pane, F. Ferrara, G. Martinelli
BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA
Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020
- 239) **C. Cerchione**, L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Frabetti, F. Pane, G. Martinelli
POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA
Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020
- 240) **C. Cerchione**, L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Mammoli, F. Pane, G. Martinelli
PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE
Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020
- 241) **C. Cerchione**, L. Catalano, D. Nappi, A.E. Pareto, G. Musuraca, A. Lucchesi, S. Ronconi, M. Ceccolini, D. Cangini, M.B. Giannini, V. Di Battista, G. Simonetti, A. Ferrari, M.T. Bochicchio, A. Ghelli Luserna di Rorà, M. Ghetti, R. Napolitano, M.C. Fontana, A. Padella, F. Pane, G. Martinelli
PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE
Hematologica Abstract Book October 2020 (SIES) Suppl.2. <https://doi.org/10.3324/haematol.2020.s2>
- 242) **C. Cerchione**, F. Alfinito, I. Soriente, A.M. D'Arco, P. Danise, G. Cerciello, G. Musuraca, A. Lucchesi, V. Di Battista, D. Cangini, M.B. Giannini, S. Ronconi, M. Ceccolini, F. Pane, G. Martinelli
ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELOYDYSPLASTIC SYNDROMES
Hematologica Abstract Book October 2020 (SIES) Suppl.2. <https://doi.org/10.3324/haematol.2020.s2>
- 243) **C. Cerchione**, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, A.E. Pareto, M. Di Perna, K. Ferrara, S. Ronconi, M. Ceccolini, D. Cangini, M.B. Giannini, V. Di Battista, G. Simonetti, A. Ferrari, M.T. Bochicchio, A. Ghelli Luserna di Rorà, M. Ghetti, R. Napolitano, M.C. Fontana, A. Padella, F. Pane, G. Martinelli
CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
Hematologica Abstract Book October 2020 (SIES) Suppl.2. <https://doi.org/10.3324/haematol.2020.s2>
- 244) **C. Cerchione**, L. Catalano, D. Nappi, A.E. Pareto, G. Musuraca, A. Lucchesi, S. Ronconi, M. Ceccolini, D. Cangini, M.B. Giannini, V. Di Battista, G. Simonetti, A. Ferrari, M.T. Bochicchio, A. Ghelli Luserna di Rorà, M. Ghetti, R. Napolitano, M.C. Fontana, A. Padella, F. Pane, G. Martinelli
POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA
Hematologica Abstract Book October 2020 (SIES) Suppl.2. <https://doi.org/10.3324/haematol.2020.s2>
- 245) **C. Cerchione**, L. Catalano, D. Nappi, S. Rocco, S. Palmieri, A. Pareto, F. Pane, F. Ferrara, G. Martinelli
Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents' era
Hematol transfus cell ther. 2020;42(S 1)
- 246) **C. Cerchione**, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, A. Pareto, F. Pane, G. Martinelli
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
Hematol transfus cell ther. 2020;42(S 1)

- 247) **C. Cerchione**, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, F. Pane, G. Martinelli
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
Hematol transfus cell ther. 2020;42(S 1)

Book Chapters:

Mieloma Multiplo - Registro tumori della Romagna – I tumori maligni in Romagna (2019, Maggioli Editore)

In compliance with the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document

25/01/2022

Claudio Cerchione, MD, PhD

